Varian Medical Systems (VAR) 10-Q 9 Aug 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Jul. 01, 2016	Jul. 29, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jul. 1, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Trading Symbol	VAR
Entity Registrant Name	VARIAN MEDICAL SYSTEMS INC
Entity Central Index Key	203,527
Current Fiscal Year End Date	--09-30
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		93,380,657

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Jul. 01, 2016	Jul. 03, 2015	Jul. 01, 2016	Jul. 03, 2015
Revenues:
Product	$ 517,271	$ 533,736	$ 1,513,366	$ 1,523,331
Service	272,148	250,275	791,953	757,940
Total revenues	789,419	784,011	2,305,319	2,281,271
Cost of revenues:
Product	332,017	363,306	1,006,460	999,581
Service	110,972	105,729	325,519	317,168
Total cost of revenues	442,989	469,035	1,331,979	1,316,749
Gross margin	346,430	314,976	973,340	964,522
Operating expenses:
Research and development	64,952	60,010	187,041	176,398
Selling, general and administrative	151,009	110,722	405,197	368,394
Total operating expenses	215,961	170,732	592,238	544,792
Operating earnings	130,469	144,244	381,102	419,730
Interest income	4,537	3,489	12,784	9,573
Interest expense	(2,906)	(1,881)	(8,448)	(5,927)
Earnings before taxes	132,100	145,852	385,438	423,376
Taxes on earnings	33,214	32,210	100,527	110,451
Net earnings	98,886	113,642	284,911	312,925
Less: Net earnings attributable to noncontrolling interests	91	136	118	136
Net earnings attributable to Varian	$ 98,795	$ 113,506	$ 284,793	$ 312,789
Net earnings per share - basic (in dollars per share)	$ 1.04	$ 1.14	$ 2.97	$ 3.13
Net earnings per share - diluted (in dollars per share)	$ 1.04	$ 1.13	$ 2.95	$ 3.10
Shares used in the calculation of net earnings per share:
Weighted average shares outstanding - basic (in shares)	94,940	99,721	95,955	100,090
Weighted average shares outstanding - diluted (in shares)	95,432	100,454	96,522	101,020

CONDENSED CONSOLIDATED STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jul. 01, 2016	Jul. 03, 2015	Jul. 01, 2016	Jul. 03, 2015
Statement of Comprehensive Income [Abstract]
Net earnings	$ 98,886	$ 113,642	$ 284,911	$ 312,925
Defined benefit pension and post-retirement plans:
Amortization of prior service cost included in net periodic benefit cost, net of tax benefit of $45 and $136 for the three and nine months ended July 1, 2016, respectively, and $41 and $121 for the corresponding periods of fiscal year 2015, respectively.	(72)	(39)	(215)	(117)
Amortization of net actuarial loss included in net periodic benefit cost, net of tax expense of ($132) and ($396) for the three and nine months ended July 1, 2016, respectively, and ($116) and ($347) for the corresponding periods of fiscal year 2015, respectively.	602	505	1,804	1,514
Defined benefit pension and post-retirement plans:	530	466	1,589	1,397
Derivative instruments:
Change in unrealized gain (loss), net of tax (expense) benefit of ($137) and $343 for the three and nine months ended July 1, 2016, respectively, and ($127) and ($866) for the corresponding periods of fiscal year 2015, respectively.	228	214	(574)	1,452
Reclassification adjustments, net of tax (expense) benefit of ($250) and ($221) for the three and nine months ended July 1, 2016, respectively, and $259 and $1,286 for the corresponding periods of fiscal year 2015, respectively.	418	(434)	368	(2,155)
Derivative instruments:	646	(220)	(206)	(703)
Available-for-sale securities:
Change in unrealized loss, net of tax benefit of $0 and $141 for the three and nine months ended July 1, 2016, respectively, and $102 for both of the corresponding periods of fiscal year 2015, respectively.	0	(218)	(299)	(218)
Reclassification adjustments, net of tax expense of ($193) for the nine months ended July 1, 2016.	0	0	411	0
Available-for-sale securities:	0	(218)	112	(218)
Currency translation adjustment	(4,270)	2,112	906	(28,348)
Other comprehensive earnings (loss)	(3,094)	2,140	2,401	(27,872)
Comprehensive earnings	95,792	115,782	287,312	285,053
Less: Comprehensive earnings attributable to noncontrolling interests	91	78	118	78
Comprehensive earnings attributable to Varian	$ 95,701	$ 115,704	$ 287,194	$ 284,975

CONDENSED CONSOLIDATED STATEME4

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jul. 01, 2016	Jul. 03, 2015	Jul. 01, 2016	Jul. 03, 2015
Statement of Comprehensive Income [Abstract]
Tax on amortization of prior service cost included in net periodic benefit cost	$ 45	$ 41	$ 136	$ 121
Tax on amortization of net actuarial loss included in net periodic benefit cost	(132)	(116)	(396)	(347)
Tax on increase (decrease) in unrealized gain on derivative instruments	(137)	(127)	343	(866)
Tax on reclassification adjustment on derivative instruments	(250)	259	(221)	1,286
Tax on increase (decrease) in unrealized gain (loss) on available for sale securities	$ 0	$ 102	141	$ 102
Tax on reclassification adjustments on available for sale securities			$ (193)

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jul. 01, 2016	Oct. 02, 2015	[1]
Current assets:
Cash and cash equivalents	$ 835,936	$ 845,468
Accounts receivable, net of allowance for doubtful accounts of $25,632 at July 1, 2016 and $21,218 at October 2, 2015	840,437	770,920
Inventories	682,490	612,607
Prepaid expenses and other current assets	187,760	163,984
Total current assets	2,546,623	2,392,979
Property, plant and equipment, net	372,496	379,215
Goodwill	282,894	283,452
Deferred tax assets	117,918	119,331
Other assets	439,521	403,673
Total assets	3,759,452	3,578,650
Current liabilities:
Accounts payable	180,338	202,918
Accrued liabilities	365,008	347,167
Deferred revenues	530,847	489,775
Advance payments from customers	140,077	178,265
Short-term borrowings	351,441	108,446
Current maturities of long-term debt	50,000	50,000
Total current liabilities	1,617,711	1,376,571
Long-term debt	300,000	337,500
Other long-term liabilities	139,554	138,235
Total liabilities	2,057,265	1,852,306
Commitments and contingencies (Note 9)
Redeemable noncontrolling interests	10,331	0
Equity:
Preferred stock of $1 par value: 1,000 shares authorized; none issued and outstanding	0	0
Common stock of $1 par value: 189,000 shares authorized; 94,306 and 98,070 shares issued and outstanding at July 1, 2016 and at October 2, 2015, respectively	94,306	98,070
Capital in excess of par value	659,033	682,167
Retained earnings	1,018,932	1,017,826
Accumulated other comprehensive loss	(84,062)	(86,463)
Total Varian stockholders' equity	1,688,209	1,711,600
Noncontrolling interests	3,647	14,744
Total equity	1,691,856	1,726,344
Total liabilities, redeemable noncontrolling interests and equity	$ 3,759,452	$ 3,578,650
[1]	The condensed consolidated balance sheet as of October 2, 2015 was derived from audited financial statements as of that date, but does not include all disclosures required by accounting principles generally accepted in the United States of America.

CONDENSED CONSOLIDATED BALANCE6

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Jul. 01, 2016	Oct. 02, 2015	[1]
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 25,632	$ 21,218
Preferred stock, par value (in dollars per share)	$ 1	$ 1
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 1	$ 1
Common stock, shares authorized (in shares)	189,000,000	189,000,000
Common stock, shares issued (in shares)	94,306,000	98,070,000
Common stock, shares outstanding (in shares)	94,306,000	98,070,000
[1]	The condensed consolidated balance sheet as of October 2, 2015 was derived from audited financial statements as of that date, but does not include all disclosures required by accounting principles generally accepted in the United States of America.

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Jul. 01, 2016		Jul. 03, 2015
Cash flows from operating activities:
Net earnings	$ 284,911		$ 312,925
Adjustments to reconcile net earnings to net cash provided by operating activities:
Share-based compensation expense	36,021		36,594
Tax benefits from exercises of share-based payment awards	1,320		12,300
Excess tax benefits from share-based compensation	(2,094)		(12,303)
Depreciation	46,709		44,893
Amortization of intangible assets	9,662		5,112
Deferred taxes	2,361		15,218
Provision for doubtful accounts receivable	5,203		2,811
Other, net	2,553		1,386
Changes in assets and liabilities, net of effects of acquisitions:
Accounts receivable	(94,637)		14,045
Inventories	(72,090)		(77,288)
Prepaid expenses and other assets	(35,396)		(32,702)
Accounts payable	(5,055)		281
Accrued liabilities and other long-term liabilities	18,765		(39,845)
Deferred revenues and advance payments from customers	6,111		32,740
Net cash provided by operating activities	204,344		316,167
Cash flows from investing activities:
Purchases of property, plant and equipment	(60,950)		(57,084)
Issuance of notes receivable	(10,301)		(5,000)
Sale of notes receivable	8,326		0
Sale of available-for-sale securities	8,638		0
Investment in available-for-sale securities	(2,509)		(942)
Acquisition of businesses, net of cash acquired	(1,244)		(11,585)
Net amounts received from (paid to) deferred compensation plan trust account	(2,907)		2,507
Other	499		(1,085)
Net cash used in investing activities	(60,448)		(73,189)
Cash flows from financing activities:
Repurchases of common stock	(374,217)		(293,570)
Proceeds from issuance of common stock to employees	36,647		86,536
Excess tax benefits from share-based compensation	2,094		12,303
Employees' taxes withheld and paid for restricted stock and restricted stock units	(10,838)		(16,200)
Borrowings under credit facility agreement	83,000		125,000
Repayments under credit facility agreement	(120,500)		(162,500)
Net borrowings under credit facility agreements with maturities less than 90 days	240,000		95,478
Contingent consideration and hold back	(5,574)		(3,341)
Capital contribution from noncontrolling interest holders	496		2,893
Net cash used in financing activities	(148,892)		(153,401)
Effects of exchange rate changes on cash and cash equivalents	(4,536)		12,585
Net increase (decrease) in cash and cash equivalents	(9,532)		102,162
Cash and cash equivalents at beginning of period	845,468	[1]	849,275
Cash and cash equivalents at end of period	$ 835,936		$ 951,437
[1]	The condensed consolidated balance sheet as of October 2, 2015 was derived from audited financial statements as of that date, but does not include all disclosures required by accounting principles generally accepted in the United States of America.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Jul. 01, 2016
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Description of Business Varian Medical Systems, Inc. (“VMS”) and its subsidiaries (collectively, the “Company”) designs, manufactures, sells and services hardware and software products for treating cancer with radiotherapy, stereotactic radiosurgery, stereotactic body radiotherapy, and brachytherapy. The Company also designs, manufactures, sells and services X-ray imaging components for use in a range of applications, including radiographic or fluoroscopic imaging, mammography, special procedures, computed tomography, computer-aided diagnostics and industrial applications. In addition, the Company designs, manufactures, sells and services linear accelerators, image processing software and image detection products for security and inspection purposes. The Company also develops, designs, manufactures, sells and services proton therapy products and systems for cancer treatment. On May 23, 2016, the Company announced its intent to separate its Imaging Components business from the remainder of its businesses through a pro rata distribution of the common stock of a new entity, named Varex Imaging Corporation (“Varex,” or “Varex Imaging”). Varex was incorporated in Delaware on July 18, 2016 for the purpose of holding the assets and liabilities associated with the Imaging Components business. Following the separation and distribution, Varex will be an independent, publicly traded company. The distribution is subject to certain conditions, including, among others, final approval of the Varian board of directors, receipt of one or more opinions with respect to certain U.S. federal income tax matters relating to the separation and the Securities and Exchange Commission ("SEC") declaring the effectiveness of the registration statement. The Company expects to complete the separation by the end of the calendar year, however there can be no assurance regarding the ultimate timing of the proposed transaction or that the transaction will be completed. Basis of Presentation The condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the SEC. Certain information and note disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements and the accompanying notes are unaudited and should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended October 2, 2015 (the “ 2015 Annual Report”). In the opinion of management, the condensed consolidated financial statements herein include adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the Company’s financial position as of July 1, 2016 and October 2, 2015 , results of operations and statements of comprehensive earnings for the three and nine months ended July 1, 2016 and July 3, 2015 , and cash flows for the nine months ended July 1, 2016 and July 3, 2015 . The results of operations for the nine months ended July 1, 2016 are not necessarily indicative of the operating results to be expected for the full fiscal year or any future period. Reclassifications In the fiscal quarter ended July 1, 2016 , the Company began presenting all deferred tax assets and liabilities as noncurrent on its Condensed Consolidated Balance Sheets as discussed further in " Accounting Pronouncements Recently Adopted " below. In addition, certain reclassifications have been made to the amounts in the prior period to conform to the current period’s presentation. Fiscal Year The fiscal years of the Company as reported are the 52- or 53-week periods ending on the Friday nearest September 30. Fiscal year 2016 is the 52-week period ending September 30, 2016 , and fiscal year 2015 was the 53-week period ended October 2, 2015 . The fiscal quarters ended July 1, 2016 and July 3, 2015 were both 13-week periods. Principles of Consolidation The condensed consolidated financial statements include those of VMS and its wholly-owned and majority-owned or controlled subsidiaries. Intercompany balances, transactions and stock holdings have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Accounting Pronouncements Recently Adopted In November 2015, the Financial Accounting Standards Board ("FASB") issued an amendment to its accounting guidance related to balance sheet classification of deferred taxes. The amendment requires that deferred tax liabilities and assets be classified as noncurrent in the Condensed Consolidated Balance Sheets. The amendment is effective for all annual periods, and interim periods within those annual periods, beginning after December 15, 2016, with early adoption permitted. The Company has adopted this amendment in the fiscal quarter ended July 1, 2016 , on a retrospective basis. To conform to the current year presentation, the Company decreased current deferred tax assets by $132.1 million and current deferred tax liabilities, which was included in accrued liabilities, by $6.3 million and increased long-term deferred tax assets by $110.0 million and decreased deferred tax liabilities, which is included in other long-term liabilities, by $15.8 million , on its Condensed Consolidated Balance Sheet as of October 2, 2015 . The adoption of this amendment had no impact to the Company’s Condensed Consolidated Statements of Earnings or Statements of Cash Flows. Recent Accounting Pronouncements or Updates Not Yet Effective In June 2016, the FASB issued an amendment to its accounting guidance related to impairment of financial instruments. The amendment adds a new impairment model that is based on expected losses rather than incurred losses. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2021 with early adoption permitted beginning in the first quarter of fiscal year 2020. The Company is evaluating the impact of adopting this amendment to its consolidated financial statements. In March 2016, the FASB issued an amendment to its accounting guidance related to employee share-based payments. The amendment simplifies several aspects of the accounting for employee share-based payments including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2018 with early adoption permitted. The Company is evaluating the impact of adopting this amendment to its consolidated financial statements. In February 2016, the FASB issued a new standard on accounting for leases. The new standard is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet. The new standard will continue to classify leases as either finance or operating, with classification affecting the pattern of expense recognition in the statement of earnings. The new standard is required to be adopted using a modified retrospective method to each prior reporting period presented with various optional practical expedients. The new standard will be effective for the Company beginning in its first quarter of fiscal year 2020 with early adoption permitted. The Company is evaluating the impact of adopting this new standard to its consolidated financial statements. In January 2016, the FASB issued an amendment to its accounting guidance related to recognition and measurement of financial assets and financial liabilities. The amendment addresses certain aspects of recognition, measurement, presentation and disclosure of financial instruments. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2019. The Company is evaluating the impact of adopting this amendment to its consolidated financial statements. In September 2015, the FASB issued a new accounting standard that eliminates the requirement to restate prior period financial statements for measurement period adjustments following a business combination. The new standard will be effective for the Company beginning in its first quarter of fiscal year 2017. The new standard is not expected to have a material impact to the Company’s consolidated financial statements. In July 2015, the FASB issued an amendment to its accounting guidance related to inventory measurement. The amendment requires inventory measured using first-in, first-out (FIFO) or average cost to be subsequently measured at the lower of cost and net realizable value, thereby simplifying the current guidance that requires an entity to measure inventory at the lower of cost or market. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2018. The amendment is not expected to have a material impact to the Company’s consolidated financial statements. In April 2015, the FASB issued an amendment to its accounting guidance related to internal use software. The amendment clarifies that the software license element of a cloud computing arrangements should be accounted for consistent with the acquisition of other software licenses. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2017. The Company is evaluating the impact of adopting this amendment to its consolidated financial statements. In April 2015, the FASB issued an amendment to its accounting guidance related to retirement benefits. The amendment provides a practical expedient that permits an entity with a fiscal year-end that does not coincide with a month-end to measure defined benefit plan assets and obligations using the month-end that is closest to the entity’s fiscal year-end. The amendment also provides a practical expedient that permits an entity that has a significant event in an interim period to remeasure defined benefit plan assets and obligations using the month-end that is closest to the date of the significant event. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2017. The amendment is not expected to have a material impact to the Company’s consolidated financial statements. In March 2015, the FASB issued an amendment to its accounting guidance related to presentation of debt issuance costs. The amendment requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2017. In August 2015, the FASB further clarified that entities are permitted to defer and present debt issuance costs related to line-of-credit arrangements as assets. These amendments are not expected to have a material impact to the Company’s consolidated financial statements. In February 2015, the FASB issued an amendment to its accounting guidance related to consolidation. The amendment modifies the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2017. The amendment is not expected to have a material impact to the Company’s consolidated financial statements. In June 2014, the FASB issued an amendment to its accounting guidance related to stock-based compensation. The amendment requires that a performance target that could be achieved after the requisite service period be treated as a performance condition that affects vesting, rather than a condition that affects the grant-date fair value. The new guidance will be effective for the Company beginning in its first quarter of fiscal year 2017. The amendment is not expected to have a material impact to the Company's consolidated financial statements. In May 2014, the FASB issued a new revenue standard, which sets forth a single, comprehensive revenue recognition model for all contracts with customers to improve comparability. The new standard requires revenue recognition to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In March 2016, the FASB amended the principal-versus-agent implementation guidance and illustrations in the new standard. In April 2016, the FASB amended the guidance on identifying performance obligations and the implementation guidance on licensing in the new standard. In May 2016, the FASB amended the guidance on collectability, noncash consideration, presentation of sales tax and transition in the new standard. The new standard will be effective for the Company beginning in its first quarter of fiscal year 2019, with early adoption permitted, but not before the first quarter of fiscal year 2018. The new standard can be applied either retrospectively to each prior reporting period presented (i.e., full retrospective adoption) or with the cumulative effect of initially applying the update recognized at the date of the initial application (i.e., modified retrospective adoption) along with additional disclosures. The Company is evaluating the impact of adopting this standard to its consolidated financial statements.

BALANCE SHEET COMPONENTS

BALANCE SHEET COMPONENTS	9 Months Ended
	Jul. 01, 2016
Balance Sheet Components [Abstract]
BALANCE SHEET COMPONENTS	BALANCE SHEET COMPONENTS The following table summarizes the Company's inventories: (In millions) July 1, October 2, Raw materials and parts $ 416.4 $ 348.3 Work-in-process 92.1 98.2 Finished goods 174.0 166.1 Total inventories $ 682.5 $ 612.6 The following tables summarize the Company's available-for-sale securities: July 1, 2016 (In millions) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Corporate debt securities: CPTC loans $ 92.4 $ — $ — $ 92.4 Total available-for-sale securities $ 92.4 $ — $ — $ 92.4 October 2, 2015 (In millions) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Corporate debt securities: CPTC loans $ 83.9 $ — $ — $ 83.9 Other 8.6 0.1 (0.3 ) 8.4 Non-U.S. government security 0.7 — — 0.7 Total available-for-sale securities $ 93.2 $ 0.1 $ (0.3 ) $ 93.0 See Note 15, "VPT Loans" for more information on California Proton Treatment Center, LLC (“CPTC”) loans. Available-for-sale securities are recorded in other assets on the Condensed Consolidated Balance Sheets because their maturity dates are greater than one year, and the Company did not intend to sell all or a portion of its loans in the next twelve months. As of July 1, 2016 , the Company anticipates that it will recover the entire amortized cost basis of all of its available-for-sale securities and determined that no other-than-temporary impairments were required to be recognized. The following table summarizes the Company's other long-term liabilities: (In millions) July 1, October 2, Long-term income taxes payable $ 44.3 $ 44.5 Deferred tax liabilities 32.6 31.7 Other 62.7 62.0 Total other long-term liabilities $ 139.6 $ 138.2

FAIR VALUE

FAIR VALUE	9 Months Ended
	Jul. 01, 2016
Fair Value Disclosures [Abstract]
FAIR VALUE	FAIR VALUE Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. There is a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: Level 1 — Quoted prices in active markets for identical assets or liabilities. Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Assets/Liabilities Measured at Fair Value on a Recurring Basis In the tables below, the Company has segregated all assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date. Fair Value Measurement Using Quoted Prices in Significant Significant Total Type of Instruments (Level 1) (Level 2) (Level 3) Balance (In millions) Assets at July 1, 2016: Available-for-sale securities: Corporate debt securities $ — $ — $ 92.4 $ 92.4 Total assets measured at fair value $ — $ — $ 92.4 $ 92.4 Liabilities at July 1, 2016: Derivative liabilities $ — $ (0.2 ) $ — $ (0.2 ) Contingent consideration — — (1.0 ) (1.0 ) Total liabilities measured at fair value $ — $ (0.2 ) $ (1.0 ) $ (1.2 ) Assets at October 2, 2015: Available-for-sale securities: Corporate debt securities $ — $ 8.4 $ 83.9 $ 92.3 Non-U.S. government security — 0.7 — 0.7 Total assets measured at fair value $ — $ 9.1 $ 83.9 $ 93.0 Liabilities at October 2, 2015: Contingent consideration $ — $ — $ (4.1 ) $ (4.1 ) Total liabilities measured at fair value $ — $ — $ (4.1 ) $ (4.1 ) The Company's available-for-sale securities are included in other assets, derivative liabilities are included in accrued liabilities at July 1, 2016 and October 2, 2015 , and contingent consideration is included in accrued liabilities at July 1, 2016 , and accrued liabilities and other long-term liabilities at October 2, 2015 on the Condensed Consolidated Balance Sheets. The fair value of the Company's Level 2 corporate debt securities and non-U.S. government security is priced using quoted market prices for similar instruments or non-binding market prices that are corroborated by observable market data. The Company has elected to use the income approach to value its derivative instruments using standard valuation techniques and Level 2 inputs, such as currency spot rates, forward points and credit default swap spreads. The Company’s derivative instruments are generally short-term in nature, typically one month to thirteen months in duration. The fair value of the Company’s Level 3 corporate debt securities, the CPTC loans, is based on the income approach by using the discounted cash flow model with key assumptions that include discount rates corresponding to the terms and risks associated with the loans to CPTC. If the estimated discount rates used were to increase or decrease, the fair value of the debt securities would decrease or increase, respectively. However, the Company does not increase the fair value of these securities above their par values as ORIX Capital Markets, LLC (“ORIX”), the loan agent, has the option to purchase these loans from the Company under the original terms and conditions at par value. The Company measures the fair value of its Level 3 contingent consideration liabilities based on the income approach by using a discounted cash flow model with key assumptions that include estimated sales units or revenues of the acquired business or completion of certain milestone targets during the earn-out period, volatility, and estimated discount rates corresponding to the periods of expected payments. If the estimated sales units, revenues or probability of completing certain milestones were to increase or decrease during the respective earn-out period, the fair value of the contingent consideration would increase or decrease, respectively. If the estimated discount rates were to increase or decrease, the fair value of contingent consideration would decrease or increase, respectively. Changes in volatility may result in an increase or decrease in the fair value of contingent consideration. The following table presents the reconciliation for all assets and liabilities measured and recorded at fair value on a recurring basis using significant unobservable inputs (Level 3): (In millions) CPTC Loans Contingent Balance at October 2, 2015 $ 83.9 $ (4.1 ) Additions (1) 8.5 — Settlements (2) — 3.5 Change in fair value recognized in earnings — (0.4 ) Balance at July 1, 2016 $ 92.4 $ (1.0 ) (1) Amounts reported under CPTC loans represent draw downs and accrued interest. (2) Amounts reported under Contingent Consideration represent cash payments to settle contingent consideration liabilities. There were no transfers of assets or liabilities between fair value measurement levels during either the three and nine months ended July 1, 2016 , or the three and nine months ended July 3, 2015 . Transfers between fair value measurement levels are recognized at the end of the reporting period. Fair Value of Other Financial Instruments The fair values of certain of the Company’s financial instruments, including bank deposits included in cash and cash equivalents, accounts receivable, net of allowance for doubtful accounts, short-term notes receivable, accounts payable, and short-term borrowings approximate their carrying amounts due to their short maturities. As of both July 1, 2016 and October 2, 2015 , the fair value of current maturities of long-term debt approximated its carrying value of $50.0 million , due to its short-term maturity. The fair value of the long-term debt payable in installments through fiscal year 2018 approximated its carrying value of $300.0 million and $337.5 million , at July 1, 2016 and October 2, 2015 , respectively, because it is carried at a market observable interest rate that resets periodically and is categorized as Level 2 in the fair value hierarchy. The fair value of the outstanding long-term notes receivable approximated their carrying value of $47.8 million and $30.9 million at July 1, 2016 and October 2, 2015 , respectively, because it is based on terms of recent comparable transactions and is categorized as Level 3 in the fair value hierarchy.

RECEIVABLES

RECEIVABLES	9 Months Ended
	Jul. 01, 2016
Receivables [Abstract]
RECEIVABLES	RECEIVABLES The following table summarizes the Company's accounts receivable and notes receivable as of July 1, 2016 and October 2, 2015 : (In millions) July 1, October 2, Accounts receivable, gross $ 915.5 $ 838.2 Allowance for doubtful accounts (25.6 ) (21.2 ) Accounts receivable, net $ 889.9 $ 817.0 Short-term $ 840.4 $ 770.9 Long-term (1) $ 49.5 $ 46.1 Notes receivable $ 53.6 $ 40.9 Short-term (2) $ 5.8 $ 10.0 Long-term (1) $ 47.8 $ 30.9 (1) Included in other assets on the Company's Condensed Consolidated Balance Sheets. (2) Included in prepaid expenses and other current assets on the Company's Condensed Consolidated Balance Sheets. A financing receivable represents a financing arrangement with a contractual right to receive money, on demand or on fixed or determinable dates, and that is recognized as an asset on the Company’s Condensed Consolidated Balance Sheets. The Company’s financing receivables consist of accounts receivable with contractual maturities of more than one year and notes receivable. A small portion of the Company's financing accounts receivables were within the short-term accounts receivable. Allowance for doubtful accounts was entirely related to the short-term accounts receivable as of July 1, 2016 and October 2, 2015 . See Note 15, "VPT Loans" for more information on the Company's long-term notes receivable balances.

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS	9 Months Ended
	Jul. 01, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND INTANGIBLE ASSETS	GOODWILL AND INTANGIBLE ASSETS The following table reflects the activity of goodwill by reportable operating segment: (In millions) Oncology Systems Imaging Components Other Total Balance at October 2, 2015 $ 158.8 $ 74.7 $ 50.0 $ 283.5 Foreign currency translation adjustments — — (0.6 ) (0.6 ) Balance at July 1, 2016 $ 158.8 $ 74.7 $ 49.4 $ 282.9 The following table reflects the gross carrying amount and accumulated amortization of the Company’s finite-lived intangible assets included in other assets on the Condensed Consolidated Balance Sheets: (In millions) July 1, October 2, Acquired existing technology $ 86.4 $ 71.7 Patents, licenses and other 35.3 35.3 Customer contracts and supplier relationship 20.7 20.1 Accumulated amortization (74.7 ) (65.1 ) Net carrying amount $ 67.7 $ 62.0 As of July 1, 2016 and October 2, 2015 , the Company also had $8.8 million and $10.6 million , respectively, of in-process research and development assets. Amortization expense for intangible assets was $2.9 million and $1.8 million in the three months ended July 1, 2016 and July 3, 2015 , respectively, and $9.7 million and $5.1 million in the nine months ended July 1, 2016 and July 3, 2015 , respectively. The Company estimates the amortization expense for the remaining three months of fiscal year 2016, fiscal years 2017 through 2020, and thereafter, will be as follows (in millions): $4.0 , $15.2 , $11.6 , $10.8 , $9.5 , and $16.6 , respectively.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Jul. 01, 2016
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS VMS has a 40% ownership interest in dpiX Holding LLC (“dpiX Holding”), a two -member consortium which has a 100% ownership interest in dpiX LLC (“dpiX”), a supplier of amorphous silicon based thin film transistor arrays (“flat panels”) for the Company’s Imaging Components’ digital image detectors, for its Oncology Systems’ On-Board Imager ® and PortalVision TM imaging products as well as the imaging system in its Varian Particle Therapy ProBeam ® system. In accordance with the dpiX Holding agreement, net profits or losses are allocated to the members, in accordance with their ownership interests. The equity investment in dpiX Holding is accounted for under the equity method of accounting. When VMS recognizes its share of net profits or losses of dpiX Holding, profits or losses in inventory purchased from dpiX are eliminated until realized by VMS. VMS recorded a loss of $0.8 million and an insignificant amount of income in the three months ended July 1, 2016 and July 3, 2015 , respectively, from its equity investment in dpiX Holding. VMS recorded a loss of $0.9 million and income of $0.5 million in the nine months ended July 1, 2016 and July 3, 2015 , respectively, from its equity investment in dpiX Holding. Income and loss on the equity investment in dpiX Holding is included in selling, general and administrative expenses in the Condensed Consolidated Statements of Earnings. The carrying value of the equity investment in dpiX Holding, which is included in other assets on the Condensed Consolidated Balance Sheets, was $47.8 million at July 1, 2016 and $47.3 million at October 2, 2015 . The Company purchased glass transistor arrays from dpiX totaling $6.4 million and $5.6 million in the three months ended July 1, 2016 and July 3, 2015 , respectively, and $16.8 million and $15.5 million in the nine months ended July 1, 2016 and July 3, 2015 , respectively. These purchases of glass transistor arrays are included as a component of inventories on the Condensed Consolidated Balance Sheets or cost of revenues - product in the Condensed Consolidated Statements of Earnings for these fiscal periods. In October 2013, VMS entered into an amended agreement with dpiX and other parties that, among other things, provides the Company with the right to 50% of dpiX’s total manufacturing capacity produced after January 1, 2014. The amended agreement requires the Company to pay for 50% of the fixed costs (as defined in the amended agreement), as determined at the beginning of each calendar year. As of July 1, 2016 , the Company had fixed cost commitments of $9.0 million related to this amended agreement through December 31, 2016. The fixed cost commitments for future periods will be determined and approved by the dpiX board of directors at the beginning of each calendar year. The amended agreement will continue unless the ownership structure of dpiX changes (as defined in the amended agreement). The Company has determined that dpiX is a variable interest entity because at-risk equity holders, as a group, lack the characteristics of a controlling financial interest. Majority votes are required to direct the manufacturing activities, legal operations and other activities that most significantly affect dpiX’s economic performance. The Company does not have majority voting rights and no power to direct the activities of dpiX and therefore is not the primary beneficiary of dpiX. The Company’s exposure to loss as a result of its involvement with dpiX is limited to the carrying value of the Company’s investment and fixed cost commitments.

BORROWINGS

BORROWINGS	9 Months Ended
	Jul. 01, 2016
Debt Disclosure [Abstract]
BORROWINGS	BORROWINGS The following table summarizes the Company's short-term and long-term debt: July 1, 2016 October 2, 2015 (Dollars in millions) Amount Weighted-Average Interest Rate Amount Weighted-Average Interest Rate Short-term debt: Current maturities of 2013 Term Loan Facility $ 50.0 1.59 % $ 50.0 1.32 % 2013 Revolving Credit Facility 330.0 1.83 % 90.0 1.57 % Sumitomo Credit Facility 21.4 0.53 % 18.4 0.63 % Total short-term debt $ 401.4 $ 158.4 Long-term debt: 2013 Term Loan Facility $ 300.0 1.59 % $ 337.5 1.32 % Total long-term debt $ 300.0 $ 337.5 On August 27, 2013 , VMS entered into an agreement (as amended to date) with certain lenders and Bank of America, N.A. (“BofA”) as administrative agent ("Credit Agreement"). The Credit Agreement provides for (i) a five -year term loan facility in an aggregate principal amount of up to $500 million (the “2013 Term Loan Facility”) and (ii) a five -year revolving credit facility in an aggregate principal amount of up to $500 million (the “2013 Revolving Credit Facility” and, collectively with the 2013 Term Loan Facility, the “2013 Credit Facility”). The 2013 Revolving Credit Facility also includes a $50 million sub-facility for the issuance of letters of credit and permits swing line loans of up to $25 million . In November 2015, the Company amended its Credit Agreement to increase the aggregate commitments under its revolving credit facility from $300 million to $500 million , reduce commitment fees and interest rate margins applicable to borrowings and increase the maximum consolidated leverage ratio that the Company must maintain. The 2013 Credit Facility contains provisions that limit the Company’s ability to pay cash dividends. The Credit Agreement will expire in August 2018. The proceeds of the 2013 Credit Facility may be used for working capital, capital expenditures, Company share repurchases, acquisitions and other corporate purposes. Borrowings under the 2013 Term Loan Facility accrue interest either (i) based on a Eurodollar Rate, as defined in the Credit Agreement (the “Eurodollar Rate”), plus a margin of 0.875% to 1.125% based on a leverage ratio involving funded indebtedness and EBITDA (earnings before interest, tax and depreciation and amortization) or (ii) based upon a base rate of (a) the federal funds rate plus 0.50% , (b) BofA’s announced prime rate, or (c) the Eurodollar Rate plus 1.00% , whichever is highest, plus a margin of up to 0.125% based on the same leverage Ratio, depending upon instructions from the Company. Borrowings under the 2013 Revolving Credit Facility accrue interest either (i) based on the Eurodollar Rate plus a margin of 1.125% to 1.375% based on a leverage ratio involving funded indebtedness and EBITDA or (ii) based upon a base rate of (a) the federal funds rate plus 0.50% , (b) BofA’s announced prime rate, or (c) the Eurodollar Rate plus 1.00% , whichever is highest, plus a margin of 0.125% to 0.375% based on the same leverage ratio, depending upon instructions from the Company. Borrowings under the 2013 Revolving Credit Facility have a maturity of approximately 30 days if based on the Eurodollar Rate and the same maturity as the 2013 Term Loan Facility if based on the base rate. The Credit Agreement provides that certain material domestic subsidiaries must guarantee the 2013 Credit Facility, subject to certain limitations on the amount guaranteed. In March 2016, the Credit Agreement was amended to provide for the release of an existing subsidiary stock pledge securing the 2013 Credit Facility and to provide that the Company will no longer be required to pledge the stock of any of its subsidiaries. The Credit Agreement contains affirmative and negative covenants applicable to the Company and its subsidiaries that are typical for credit facilities of this type, and that are subject to materiality and other qualifications, carve-outs, baskets and exceptions. The Company has also agreed to maintain certain financial covenants including (i) a maximum consolidated leverage ratio, involving funded indebtedness and EBITDA, and (ii) a minimum cash flow coverage ratio. The Company was in compliance with all covenants under the Credit Agreement for all periods within these condensed consolidated financial statements in which it was in existence. VMS’s Japanese subsidiary (“VMS KK”) has an unsecured uncommitted credit agreement with Sumitomo that enables VMS KK to borrow and have outstanding at any given time a maximum of 3 billion Japanese Yen (the “Sumitomo Credit Facility”). In February 2016, the Sumitomo Credit Facility was extended and will expire in February 2017 . Borrowings under the Sumitomo Credit Facility accrue interest based on the basic loan rate announced by the Bank of Japan plus a margin of 0.5% per annum.

DERIVATIVE INSTRUMENTS AND HEDG

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	9 Months Ended
	Jul. 01, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES The Company measures all derivatives at fair value on the Condensed Consolidated Balance Sheets. The accounting for gains or losses resulting from changes in the fair value of those derivatives depends upon the use of the derivative and whether it qualifies for hedge accounting. The fair values of derivative instruments reported on the Company’s Condensed Consolidated Balance Sheets were as follows: Liability Derivatives Balance Sheet July 1, October 2, (In millions) Location Fair Value Fair Value Derivatives designated as hedging instruments: Foreign exchange forward contracts Accrued liabilities $ 0.2 $ — Total derivatives $ 0.2 $ — At July 1, 2016 and October 2, 2015 , the fair value of the Company's derivative assets, and derivative liabilities not designated as hedging instruments was immaterial. See Note 3, "Fair Value" regarding valuation of the Company’s derivative instruments. Also see Note 1, "Summary of Significant Accounting Policies" in the Consolidated Financial Statements in the Company’s 2015 Annual Report regarding credit risk associated with the Company’s derivative instruments. Offsetting of Derivatives The Company presents its derivative assets and derivative liabilities on a gross basis on the Condensed Consolidated Balance Sheets. However, under agreements containing provisions on netting with certain counterparties of foreign exchange contracts, subject to applicable requirements, the Company is allowed to net-settle transactions on the same date in the same currency, with a single net amount payable by one party to the other. As of July 1, 2016 and October 2, 2015 , there were no potential effects of rights of setoff associated with derivative instruments. The Company is neither required to pledge nor entitled to receive cash collateral related to these derivative transactions. Cash Flow Hedging Activities The Company designates and accounts for certain of its hedges of forecasted foreign currency revenues as cash flow hedges. The Company’s designated cash flow hedges de-designate when the anticipated revenues associated with the transactions are recognized and the effective portion in accumulated other comprehensive loss on the Condensed Consolidated Balance Sheets is reclassified to revenues in the Condensed Consolidated Statements of Earnings. Subsequent changes in fair value of the derivative instrument are recorded in selling, general and administrative expenses in the Condensed Consolidated Statements of Earnings to offset changes in fair value of the resulting non-functional currency receivables. For derivative instruments that are designated and qualify as cash flow hedges, the Company formally documents for each derivative instrument at the hedge’s inception the relationship between the hedging instrument (foreign currency forward contract) and hedged item (forecasted foreign currency revenues), the nature of the risk being hedged, and its risk management objective and strategy for undertaking the hedge. The Company records the effective portion of the gain or loss on the derivative instruments that are designated and qualify as cash flow hedges in accumulated other comprehensive loss on the Condensed Consolidated Balance Sheets and reclassifies these amounts into revenues in the Condensed Consolidated Statements of Earnings in the period during which the hedged transaction is recognized in earnings. The Company assesses hedge effectiveness both at the onset of the hedge and on an ongoing basis using regression analysis. The Company measures hedge ineffectiveness by comparing the cumulative change in the fair value of the effective component of the hedge contract with the cumulative change in the fair value of the hedged item. The Company recognizes any over performance of the derivative as ineffectiveness in revenues, and time value amounts excluded from the assessment of effectiveness in cost of revenues in the Condensed Consolidated Statements of Earnings. During the nine months ended July 1, 2016 , the Company did not discontinue any cash flow hedges. At the inception of the hedge relationship and quarterly thereafter, the Company assesses whether the likelihood of meeting the forecasted cash flow is highly probable. As of July 1, 2016 , all forecasted cash flows were still probable to occur. As of July 1, 2016 , the net unrealized loss on derivative instruments, before tax, of $0.3 million was included in accumulated other comprehensive loss and is expected to be reclassified to earnings over the next 12 months that follows. The Company had the following outstanding foreign currency forward contracts that were entered into to hedge forecasted revenues and designated as cash flow hedges: July 1, 2016 (In millions) Notional Euro $ 16.5 Totals $ 16.5 The following table presents the amounts, before tax, recognized in accumulated other comprehensive loss on the Condensed Consolidated Balance Sheets and in the Condensed Consolidated Statements of Earnings that are related to the effective portion of the foreign currency forward contracts designated as cash flow hedges: Gain (Loss) Recognized in Other Comprehensive Income (Effective Portion) Location of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Net Earnings (Effective Portion) Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Net Earnings (Effective Portion) Three Months Ended Nine Months Ended Three Months Ended Nine Months Ended (In millions) July 1, July 3, July 1, July 3, July 1, July 3, July 1, July 3, Foreign currency forward contracts $ 0.4 $ 0.3 $ (0.9 ) $ 2.3 Revenues $ (0.7 ) $ 0.7 $ (0.6 ) $ 3.4 Balance Sheet Hedging Activities The Company also hedges balance sheet exposures from its various subsidiaries and business units where the U.S. Dollar is the functional currency. The Company enters into foreign currency forward contracts to minimize the short-term impact of foreign currency fluctuations on monetary assets and liabilities denominated in currencies other than the U.S. Dollar functional currency. The foreign currency forward contracts are short term in nature, typically with a maturity of approximately one month , and are based on the net forecasted balance sheet exposure. These hedging instruments do not qualify for hedge accounting treatment. For derivative instruments not designated as hedging instruments, changes in their fair values are recognized in selling, general and administrative expenses in the Condensed Consolidated Statements of Earnings. Changes in the values of these hedging instruments are offset by changes in the values of foreign-currency-denominated assets and liabilities. Variations from the forecasted foreign currency assets or liabilities, coupled with a significant currency rate movement, may result in a material gain or loss if the hedges are not effectively offsetting the change in value of the foreign currency asset or liability. Other than foreign exchange hedging activities, the Company has no other free-standing or embedded derivative instruments. The Company had the following outstanding foreign currency forward contracts that were entered into to hedge balance sheet exposures from its various foreign subsidiaries and business units: July 1, 2016 (In millions) Notional Notional Australian Dollar $ 18.8 $ — Brazilian Real 9.0 — British Pound 66.2 — Canadian Dollar — 4.8 Euro 184.9 9.0 Hungarian Forint 3.5 — Indian Rupee 12.7 — Japanese Yen 82.7 — New Zealand Dollar 1.5 — Swedish Krona 1.8 — Swiss Franc — 82.6 Thai Baht 4.4 — Totals $ 385.5 $ 96.4 The following table presents the gains recognized in the Condensed Consolidated Statements of Earnings related to the foreign currency forward exchange contracts that are not designated as hedging instruments: Location of Gain (Loss) Recognized in Income on Derivative Instruments Amount of Gain (Loss) Recognized in Net Earnings on Derivative Instruments Three Months Ended Nine Months Ended (In millions) July 1, July 3, July 1, July 3, Selling, general and administrative expenses $ 1.5 $ (1.3 ) $ (3.4 ) $ 32.7 The gains or losses on these derivative instruments were significantly offset by the gains or losses resulting from the remeasurement of monetary assets and liabilities denominated in currencies other than the U.S. Dollar functional currency. Contingent Features Certain of the Company’s derivative instruments are subject to master agreements which contain provisions that require the Company, in the event of a default, to settle the outstanding contracts in net liability positions by making settlement payments in cash or by setting off amounts owed to the counterparty against any credit support or collateral held by the counterparty. As of July 1, 2016 and October 2, 2015 , the Company did not have significant outstanding derivative instruments with credit-risk-related contingent features that were in a net liability position.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Jul. 01, 2016
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Product Warranty The following table reflects the changes in the Company’s accrued product warranty: Nine Months Ended July 1, July 3, (In millions) 2016 2015 Accrued product warranty, at beginning of period $ 45.9 $ 49.3 Charged to cost of revenues 39.6 33.1 Actual product warranty expenditures (35.5 ) (38.8 ) Accrued product warranty, at end of period $ 50.0 $ 43.6 Accrued product warranty was included in accrued liabilities and other long-term liabilities on the Condensed Consolidated Balance Sheets as of July 1, 2016 and October 2, 2015 . Other Commitments See Note 15, "VPT Loans" for additional information about the Company's commitments for funding development and construction of various proton therapy centers. Contingencies Environmental Remediation Liabilities The Company’s operations and facilities, past and present, are subject to environmental laws, including laws that regulate the handling, storage, transport and disposal of hazardous substances. Certain of those laws impose cleanup liabilities under certain circumstances. In connection with those laws and certain of the Company’s past and present operations and facilities, the Company oversees various environmental cleanup projects and also reimburses certain third parties for cleanup activities. Those include facilities sold as part of the Company’s electron devices business in 1995 and thin film systems business in 1997. In addition, the U.S. Environmental Protection Agency (“EPA”) or third parties have named the Company as a potentially responsible party under the amended Comprehensive Environmental Response Compensation and Liability Act of 1980 (“CERCLA”), at sites to which the Company or the facilities of the sold businesses were alleged to have shipped waste for recycling or disposal (the “CERCLA sites”). In connection with the CERCLA sites, the Company to date has been required to pay only a small portion of the total amount as its contributions to cleanup efforts. Under the agreement that governs the spin-offs of Varian, Inc., which was acquired by Agilent Technologies Inc. (the successor entity hereinafter referred to as “VI”), and Varian Semiconductor Equipment Associates, Inc., which was acquired by Applied Materials, Inc. (the successor entity hereinafter referred to as “VSEA”), VI and VSEA are each obligated to indemnify the Company for one-third of the environmental cleanup costs associated with corporate, discontinued or sold operations prior to the spin-offs (after adjusting for any insurance proceeds or tax benefits received by the Company), as well as fully indemnify the Company for other liabilities arising from the operations of the business transferred to it as part of the spin-offs. The Company spent $0.3 million and $0.2 million (net of amounts borne by VI and VSEA) in the three months ended July 1, 2016 and July 3, 2015 , respectively, on environmental cleanup costs, third-party claim costs, project management costs and legal costs. The Company spent $0.7 million and $1.0 million (net of amounts borne by VI and VSEA) in the nine months ended July 1, 2016 and July 3, 2015 , respectively, on such costs. Inherent uncertainties make it difficult to estimate the likelihood of the cost of future cleanup, third-party claims, project management and legal services for the CERCLA sites and one of the Company’s past facilities. Nonetheless, as of July 1, 2016 , the Company estimated that, net of VI’s and VSEA’s indemnification obligations, future costs associated with the CERCLA sites and this facility would range in total from $1.3 million to $9.9 million . The time frames over which these cleanup project costs are estimated vary, ranging from one year to thirty years as of July 1, 2016 . Management believes that no amount in that range is more probable of being incurred than any other amount and therefore accrued $1.3 million for these cleanup projects as of July 1, 2016 . The accrued amount has not been discounted to present value due to the uncertainties that make it difficult to develop a single best estimate. The Company believes it has gained sufficient knowledge to better estimate the scope and cost of monitoring, cleanup and management activities for its other past and present facilities. This, in part, is based on agreements with other parties and also cleanup plans approved by or completed in accordance with the requirements of the governmental agencies having jurisdiction. As of July 1, 2016 , the Company estimated that the Company’s future exposure, net of VI’s and VSEA’s indemnification obligations, for the costs at these facilities, and reimbursements of third-party’s claims for these facilities, ranged in total from $5.6 million to $25.8 million . The time frames over which these costs are estimated to be incurred vary, ranging from one year to thirty years as of July 1, 2016 . As to each of these facilities, management determined that a particular amount within the range of estimated costs was a better estimate than any other amount within the range, and that the amount and timing of these future costs were reliably determinable. The best estimate within that range was $8.4 million at July 1, 2016 . Accordingly, the Company has accrued $7.1 million for these costs, which represents the best estimate discounted at 4% , net of inflation. This accrual is in addition to the $1.3 million described in the preceding paragraph. These amounts are only estimates of anticipated future costs. The amounts the Company will actually spend may be greater or less than these estimates, even as the Company believes the degree of uncertainty will narrow as cleanup activities progress. While the Company believes its reserve is adequate, as the scope of the Company’s obligations becomes more clearly defined, the Company may modify the reserve, and charge or credit future earnings accordingly. Nevertheless, based on information currently known to management, and assuming VI and VSEA satisfy their indemnification obligations, management believes the costs of these environmental-related matters are not reasonably likely to have a material adverse effect on the consolidated financial statements of the Company in any one fiscal year. The Company evaluates its liability for investigation and cleanup costs in light of the obligations and apparent financial strength of potentially responsible parties and insurance companies with respect to which the Company believes it has rights to indemnity or reimbursement. The Company has asserted claims for recovery of environmental investigation and cleanup costs already incurred, and to be incurred in the future against various insurance companies and other third parties. The Company receives certain cash payments in the form of settlements and judgments from defendants, insurers and other third parties from time to time. The Company has also reached an agreement with an insurance company under which that insurer has agreed to pay a portion of the Company’s past and future environmental-related expenditures. Receivables, net of VI’s and VSEA’s portion, from that insurer amounted to $2.1 million at both July 1, 2016 and October 2, 2015 , with the noncurrent receivables portion included in other assets and the payable portion to that insurer is included in other long-term liabilities on the Condensed Consolidated Balance Sheets. The Company believes that this receivable is recoverable because it is based on a binding, written settlement agreement with what appears to be a financially viable insurance company, and the insurance company has paid the Company’s claims in the past. The availability of the indemnities of VI and VSEA will depend upon the future financial strength of VI and VSEA. Given the long-term nature of some of the liabilities, VI and VSEA may be unable to fund the indemnities in the future. It is also possible that a court would disregard this contractual allocation among the parties and require the Company to assume responsibility for obligations allocated to another party, particularly if the other party were to refuse or was unable to pay any of its allocated shares. The agreement governing the spin-offs generally provides that if a court prohibits a company from satisfying its shared indemnification obligations, the indemnification obligations will be shared equally by the two other companies. Other Matters From time to time, the Company is a party to or otherwise involved in legal proceedings, claims and government inspections or investigations and other legal matters, both inside and outside the United States, arising in the ordinary course of its business or otherwise. The Company accrues amounts, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss (including, among other things, probable settlement value). A loss or a range of loss is disclosed when it is reasonably possible that a material loss will be incurred and can be estimated or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision. In September 2015, Elekta Ltd. and William Beaumont Hospital served the Company with a complaint alleging infringement of patents related to certain aspects of cone beam imaging in conjunction with radiotherapy. During September 2015 and October 2015, the Company filed several complaints in the U.S. and foreign courts and the U.S. International Trade Commission against Elekta AB and its subsidiaries alleging infringement of various patents relating to certain aspects of cone beam imaging, cone-beam imaging gantries, volumetric modulated arc therapy (“VMAT”), and combined magnetic resonance imaging linear accelerator systems. In February 2016, Elekta Ltd. filed several complaints in the U.S. and foreign courts alleging infringement of certain patents related to linear accelerator control systems and treatment planning. These lawsuits are ongoing and at this time, the Company is unable to predict the ultimate outcomes of these matters. Therefore, no amounts have been accrued as of July 1, 2016 . In June 2015, a foreign subsidiary of the Company was charged by the Department for Investigation and Penal Action of Lisbon with alleged improper activities relating to three tenders of medical equipment in Portugal during the period of 2003 to 2009. The Company has requested a judicial review available under Portuguese criminal procedure processes as to whether or not such charges are proper under Portuguese law. The Company previously undertook an internal investigation of this matter and voluntarily disclosed the results of this investigation to the U.S. Department of Justice and the U.S. Securities and Exchange Commission. At this time, the Company is unable to predict the ultimate outcome of this matter, and therefore no amounts have been accrued as of July 1, 2016 . In addition to the above, the Company is involved in other legal matters. However, such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company is unable to estimate a range of reasonably possible losses with respect to such matters. There can be no assurances as to whether the Company will become subject to significant additional claims and liabilities with respect to ongoing or future proceedings. If actual liabilities significantly exceed the estimates made, the Company’s consolidated financial position, results of operations or cash flows could be materially adversely affected. Legal expenses relating to legal matters are expensed as incurred. Restructuring Charges As part of the Company's plan to enhance operational performance through productivity initiatives, the Company implemented a workforce reduction, primarily in its Oncology Systems and Imaging Components segments, in the first quarter of fiscal year 2016. The Company incurred $0.8 million and $5.6 million in restructuring charges during the three and nine months ended July 1, 2016, in connection with the restructuring program, of which $3.5 million was paid in cash during the nine months ended July 1, 2016 . The restructuring charges are included in selling, general and administrative expenses in the Condensed Consolidated Statements of Earnings. The Company expects to substantially complete this restructuring program by the middle of fiscal year 2017, and any remaining restructuring charges relating to this program are not expected to be material. The Company incurred $13.4 million in restructuring charges related to an enhanced retirement program and workforce reduction during the nine months ended July 3, 2015 .

RETIREMENT PLANS

RETIREMENT PLANS	9 Months Ended
	Jul. 01, 2016
Compensation and Retirement Disclosure [Abstract]
RETIREMENT PLANS	RETIREMENT PLANS The Company sponsors seven defined benefit pension plans for regular full time employees in Germany, Japan, Switzerland, the Philippines and the United Kingdom. The Company also sponsors a post-retirement benefit plan that provides healthcare benefits to certain eligible retirees in the United States. Two of the Company's defined benefit pension plans including one in Germany and one in the Philippines and the Company's post-retirement benefit plan are not presented in the following information as they are not material. The components of net defined benefit costs were as follows: Three Months Ended Nine Months Ended (In millions) July 1, July 3, July 1, July 3, Defined Benefit Plans Service cost $ 1.5 $ 1.2 $ 4.5 $ 3.6 Interest cost 1.0 1.3 3.0 3.9 Expected return on plan assets (1.7 ) (1.8 ) (5.1 ) (5.4 ) Amortization of prior service cost — — — 0.1 Recognized actuarial loss 0.7 0.6 2.2 1.8 Net periodic benefit cost $ 1.5 $ 1.3 $ 4.6 $ 4.0

INCOME TAXES

INCOME TAXES	9 Months Ended
	Jul. 01, 2016
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company’s effective tax rate was 25.1% and 22.1% for the three months ended July 1, 2016 and July 3, 2015 , respectively, and 26.1% for both the nine months ended July 1, 2016 and July 3, 2015 . The increase in the Company’s effective tax rate during the three months ended July 1, 2016, compared to the year ago period, was primarily due to the geographic mix of earnings; specifically, the three months ended July 3, 2015 included significant VPT earnings in Germany, a jurisdiction for which the Company has a full valuation allowance. The Company’s effective income tax rate differs from the U.S. federal statutory rate primarily because the Company’s foreign earnings are taxed at rates that are, on average, lower than the U.S. federal rate, and because the Company’s domestic earnings are subject to state income taxes. The total amount of unrecognized tax benefits did not materially change during the nine months ended July 1, 2016 ; however, the amount of unrecognized tax benefits has increased as a result of positions taken during the current and prior years, and has decreased as the result of the expiration of the statutes of limitation in various jurisdictions.

STOCKHOLDERS' EQUITY AND NONCON

STOCKHOLDERS' EQUITY AND NONCONTROLLING INTERESTS	9 Months Ended
	Jul. 01, 2016
Equity [Abstract]
STOCKHOLDERS’ EQUITY AND NONCONTROLLING INTERESTS	STOCKHOLDERS’ EQUITY AND NONCONTROLLING INTERESTS Share Repurchase Program In November 2015, the VMS Board of Directors authorized the repurchase of 8.0 million shares of VMS common stock through December 31, 2016. Share repurchases under the Company's authorizations may be made in open market purchases, in privately negotiated transactions (including accelerated share repurchase (“ASR”) programs), or under Rule 10b5-1 share repurchase plans, and may be made from time to time in one or more blocks. All shares that were repurchased under the Company's share repurchase programs have been retired. The Company repurchased shares of VMS common stock under various authorizations during the periods presented as follows: Three Months Ended Nine Months Ended (In thousands, except per share amounts) July 1, July 3, July 1, July 3, Number of shares 1,500 1,000 4,650 3,325 Average repurchase price per share $ 83.68 $ 92.39 $ 80.48 $ 88.30 Total cost $ 125,513 $ 92,389 $ 374,217 $ 293,570 Included in the table above, VMS repurchased common stock under various ASR agreements during the periods presented as follows: Three Months Ended Nine Months Ended (In thousands, except per share amounts) July 1, July 3, July 1, July 3, Number of shares — 744 519 1,239 Average repurchase price per share $ — $ 94.10 $ 77.81 $ 92.84 Total cost $ — $ 70,000 $ 40,400 $ 115,000 As of July 1, 2016 , 4.8 million shares of VMS common stock remained available for repurchase under the November 2015 authorization. Subsequent to July 1, 2016 , the Company paid $45.4 million , as part of an ASR agreement with J.P. Morgan Chase Bank, N.A. (“J.P. Morgan”), and received approximately 0.5 million shares of VMS common stock. Other Comprehensive Earnings The changes in accumulated other comprehensive loss by component and related tax effects are summarized as follows: (In thousands) Net Unrealized Gains Net Net Cumulative Accumulated Balance at October 2, 2015 $ (46,070 ) $ — $ (112 ) $ (40,281 ) $ (86,463 ) Other comprehensive earnings (loss) before reclassifications — (917 ) (440 ) 906 (451 ) Amounts reclassified out of other comprehensive earnings 1,849 589 604 — 3,042 Tax benefit (expense) (260 ) 122 (52 ) — (190 ) Balance at July 1, 2016 $ (44,481 ) $ (206 ) $ — $ (39,375 ) $ (84,062 ) (In thousands) Net Unrealized Gain Net Net Cumulative Accumulated Balance at September 26, 2014 $ (44,060 ) $ 965 $ — $ (15,516 ) $ (58,611 ) Other comprehensive earnings (loss) before reclassifications — 2,318 (320 ) (28,348 ) (26,350 ) Amounts reclassified out of other comprehensive earnings 1,623 (3,441 ) — (1,818 ) Tax benefit (expense) (226 ) 420 102 — 296 Balance at July 3, 2015 $ (42,663 ) $ 262 $ (218 ) $ (43,864 ) $ (86,483 ) The amounts reclassified out of other comprehensive earnings into the Condensed Consolidated Statements of Earnings, with line item location, during each period were as follows: Three Months Ended Nine Months Ended July 1, July 3, July 1, July 3, (In thousands) 2016 2015 2016 2015 Comprehensive Earnings Components Income (Loss) Before Taxes Income (Loss) Before Taxes Line Item in Statements of Earnings Unrealized loss on defined benefit pension and post-retirement benefit plans $ (617 ) $ (541 ) $ (1,849 ) $ (1,623 ) Cost of revenues & Operating expenses Unrealized gain (loss) on cash flow hedging instruments (668 ) 693 (589 ) 3,441 Revenues Unrealized loss on available-for-sale-investments — — (604 ) — Operating expenses Total amounts reclassified out of other comprehensive earnings $ (1,285 ) $ 152 $ (3,042 ) $ 1,818 Noncontrolling Interests In April 2015, the Company completed the acquisition of 73.5% of the then outstanding shares of MeVis Medical Solutions AG ("MeVis"), a public company based in Bremen, Germany that provides image processing software and services for cancer screening. In August 2015, the Company, through one of its German subsidiaries, entered into a domination and profit and loss transfer agreement (the “DPLTA”) with MeVis. In October 2015, the DPLTA became effective upon its registration at the local court of Bremen, Germany. Under the DPLTA, MeVis subordinates its management to the Company and undertakes to transfer all of its annual profits and losses to the Company. In return, the DPLTA grants the noncontrolling shareholders of MeVis: (1) an annual recurring net compensation of €0.95 per MeVis share starting from January 1, 2015 and (2) a put right for their MeVis shares at €19.77 per MeVis share. Upon effectiveness of the DPLTA, the noncontrolling interests in MeVis became redeemable as a result of the put right and were reclassified to temporary equity. As of July 1, 2016 , the redemption value of redeemable noncontrolling interests in MeVis was $10.3 million . During the nine months ended July 1, 2016 , an immaterial number of MeVis' shares were purchased under the put right. As of July 1, 2016 , noncontrolling shareholders together held approximately 480,000 shares of MeVis, representing 26.4% of the outstanding shares. Changes in noncontrolling interests and redeemable noncontrolling interests relating to MeVis and other subsidiaries of the Company were as follows: Nine Months Ended Nine Months Ended July 1, 2016 July 3, 2015 (In thousands) Noncontrolling Interests Redeemable Noncontrolling Interests Noncontrolling Interests Redeemable Noncontrolling Interests Balance at beginning of period $ 14,744 $ — $ — $ — Net earnings (loss) attributable to noncontrolling interests (216 ) 334 136 — Acquisition of Mevis — — 10,218 Capital contribution from noncontrolling interest holders — — 3,993 — Reclassification of noncontrolling interests in MeVis to redeemable noncontrolling interests (10,382 ) 10,382 — — Other (499 ) (385 ) 21 — Balance at end of period $ 3,647 $ 10,331 $ 14,368 $ —

EARNINGS PER SHARE

EARNINGS PER SHARE	9 Months Ended
	Jul. 01, 2016
Earnings Per Share [Abstract]
EARNINGS PER SHARE	EARNINGS PER SHARE Basic net earnings per share is computed by dividing net earnings attributable to Varian by the weighted average number of shares of VMS common stock outstanding for the period. Diluted net earnings per share is computed by dividing net earnings attributable to Varian by the sum of the weighted average number of common shares outstanding and dilutive common shares under the treasury stock method. The following table sets forth the computation of basic and diluted net earnings per share: Three Months Ended Nine Months Ended (In thousands, except per share amounts) July 1, July 3, July 1, July 3, Net earnings attributable to Varian $ 98,795 $ 113,506 $ 284,793 $ 312,789 Weighted average shares outstanding - basic 94,940 99,721 95,955 100,090 Dilutive effect of potential common shares 492 733 567 930 Weighted average shares outstanding - diluted 95,432 100,454 96,522 101,020 Net earnings per share attributable to Varian - basic $ 1.04 $ 1.14 $ 2.97 $ 3.13 Net earnings per share attributable to Varian - diluted $ 1.04 $ 1.13 $ 2.95 $ 3.10 Anti-dilutive employee shared based awards, excluded 2,014 948 2,016 994 The Company excludes potentially dilutive common shares (consisting of shares underlying stock options and the employee stock purchase plan) from the computation of diluted weighted average shares outstanding if the per share value, either the exercise price of the awards or the sum of (a) the exercise price of the awards and (b) the amount of the compensation cost attributed to future services and not yet recognized and (c) the amount of tax benefit or shortfall that would be recorded in additional paid-in capital when the award becomes deductible, is greater than the average market price of the shares, because the inclusion of the shares underlying these stock awards would be anti-dilutive to earnings per share.

EMPLOYEE STOCK PLANS

EMPLOYEE STOCK PLANS	9 Months Ended
	Jul. 01, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
EMPLOYEE STOCK PLANS	EMPLOYEE STOCK PLANS The table below summarizes the net share-based compensation expense recognized for employee stock awards and for the option component of the employee stock purchase plan shares: Three Months Ended Nine Months Ended (In thousands) July 1, July 3, July 1, July 3, Cost of revenues - Product $ 1,033 $ 1,263 $ 3,141 $ 3,578 Cost of revenues - Service 1,114 1,066 3,063 3,004 Research and development 1,723 1,717 5,046 5,109 Selling, general and administrative 8,346 7,310 24,771 24,903 Total share-based compensation expense $ 12,216 $ 11,356 $ 36,021 $ 36,594 Income tax benefit for share-based compensation $ (3,701 ) $ (3,455 ) $ (10,958 ) $ (11,371 ) During the nine months ended July 1, 2016 and July 3, 2015 , the Company granted performance units to certain employees under the Third Amended 2005 Plan. The number of shares of VMS common stock ultimately issued under the performance units at vesting depends on the Company’s business performance during the performance period, against specified performance targets, both of which are set by the Compensation and Management Development Committee of the Board of Directors. The performance units vest at the end of a three -year service period. Performance units granted prior to fiscal year 2015 have one three -year performance period for both the Company's performance and total shareholder return, performance units granted in fiscal year 2015 have a one year Company performance period and a three year total shareholder return, and performance units awarded in fiscal year 2016 have three separate one -year Company performance periods and a three year total shareholder return. Subject to certain exceptions, any unvested performance unit awards are forfeited at the time of termination. The fair value of options granted was estimated at the date of grant using the Black-Scholes model with the following weighted average assumptions: Three Months Ended Nine Months Ended July 1, July 3, July 1, July 3, Employee Stock Option Plans Expected term (in years) 4.13 4.13 4.13 4.15 Risk-free interest rate 1.2 % 1.3 % 1.1 % 1.3 % Expected volatility 20.5 % 21.6 % 20.1 % 22.1 % Expected dividend — % — % — % — % Weighted average fair value at grant date $ 15.29 $ 17.16 $ 13.71 $ 18.52 The option component of employee stock purchase plan shares was estimated at the date of grant using the Black-Scholes model with the following weighted average assumptions: Three Months Ended Nine Months Ended July 1, July 3, July 1, July 3, Employee Stock Purchase Plan Expected term (in years) 0.50 0.50 0.50 0.50 Risk-free interest rate 0.4 % 0.1 % 0.3 % 0.1 % Expected volatility 18.3 % 17.2 % 17.6 % 12.7 % Expected dividend — % — % — % — % Weighted average fair value at grant date $ 16.60 $ 17.56 $ 16.09 $ 15.87 A summary of share-based awards available for grant is as follows: (In thousands) Shares Available for Grant Balance at October 2, 2015 6,661 Granted (2,327 ) Cancelled or expired 277 Balance at July 1, 2016 4,611 Awards other than stock options set forth in the table were calculated under the Third Amended 2005 Plan as 2.6 shares for every one share awarded. The shares available for grant is further adjusted to reflect a maximum payout that could be issued for each performance unit granted. The maximum payouts that could be issued for each performance unit granted are 1.75 shares beginning in fiscal year 2016, 2.0 shares in fiscal year 2015 and 1.5 shares prior to fiscal year 2015. Activity under the Company’s employee stock plans is presented below: Options Outstanding (In thousands, except per share amounts) Number of Weighted Weighted Aggregate Balance at October 2, 2015 2,537 $ 72.58 Granted 828 75.97 Cancelled or expired (23 ) 85.95 Exercised (377 ) 52.02 Balance at July 1, 2016 2,965 $ 76.03 4.6 $ 26,060 Exercisable at July 1, 2016 1,664 $ 72.13 3.4 $ 20,556 (1) The aggregate intrinsic value represents the total pre-tax intrinsic value of options, which is computed based on the difference between the exercise price and VMS’s closing common stock price of $82.60 as of July 1, 2016 , the last trading date of the third quarter of fiscal year 2016 , and which would have been received by the option holders had all option holders exercised and sold their options as of that date. As of July 1, 2016 , there was $13.5 million of total unrecognized compensation expense related to outstanding stock options. This unrecognized compensation expense is expected to be recognized over a weighted average period of 1.7 years. The activity for restricted stock, restricted stock units, deferred stock units and performance units is summarized as follows: (In thousands, except per share amounts) Number of Weighted Average Balance at October 2, 2015 950 $ 84.11 Granted 485 77.89 Vested (389 ) 80.98 Cancelled or expired (75 ) 81.86 Balance at April 1, 2016 971 $ 82.36 As of July 1, 2016 , unrecognized compensation expense totaling $45.3 million was related to awards of restricted stock, restricted stock units, deferred stock units and performance units. This unrecognized compensation expense is expected to be recognized over a weighted average period of 1.9 years.

VPT LOANS

VPT LOANS	9 Months Ended
	Jul. 01, 2016
Receivables [Abstract]
VPT LOANS	VPT LOANS The following table lists the Company's outstanding loans and commitments for funding development and construction of various proton therapy centers: July 1, 2016 October 2, 2015 (In millions) Balance Commitment Balance Commitment Long-term notes receivable (1) : NYPC loan $ 18.5 $ — $ 18.7 $ 72.8 MPTC loans (2) 29.3 22.8 12.2 22.8 $ 47.8 $ 22.8 $ 30.9 $ 95.6 Available-for-sale Securities (1) : CPTC loans $ 92.4 $ 1.9 $ 83.9 $ — $ 92.4 $ 1.9 $ 83.9 $ — (1) Included in other assets on the Company's Condensed Consolidated Balance Sheets. (2) Increase in balance was primarily due to a $17.0 million conversion from long-term unbilled accounts receivable to long-term notes receivable. New York Proton Center ("NYPC") Loan In July 2015, the Company, through one of its subsidiaries, committed to loan up to $91.5 million to MM Proton I, LLC ("MMI") in connection with a purchase agreement to supply a proton system to equip NYPC. The commitment included a $73.0 million “Senior First Lien Loan” with a six -year term at 9% interest and an $18.5 million “Subordinate Loan” with a six-and-a-half-year term at up to 13.5% interest. The Company's entire commitment of the Subordinate Loan was drawn down in fiscal year 2015. In June 2016, the Company assigned to Deutsche Bank AG ("Deutsche Bank") its entire $73.0 million Senior First Lien Loan commitment. As of the date of the assignments, $10.5 million in aggregate principal amount of Senior First Lien Loan commitments had been funded by the Company. The total consideration paid by Deutsche Bank to the Company in consideration for the assignment was approximately $8.3 million in cash, representing the funded portion, less a discount of 3% of the Company's total Senior First Lien Loan commitment, both funded and unfunded. The Company recorded a $2.2 million impairment associated with the sale of the loan in selling, general and administrative in the three months ended July 1, 2016 . In addition to the outstanding loan, the Company had $15.3 million , as of July 1, 2016 , in accounts receivable, which includes unbilled accounts receivable, from NYPC. As of October 2, 2015 , the Company did not have any accounts receivable from NYPC. Maryland Proton Therapy Center ("MPTC") Loans In May 2015, the Company, through one of its subsidiaries, committed to loan up to $35.0 million to MPTC, which included rolling over an existing loan for $10.0 million plus $2.2 million of previously accrued interest. The Company had previously entered into an agreement with MPTC to supply it with a proton system. Varian's commitment is in the form of a subordinated loan that is due, with accrued interest, in three annual payments from 2020 to 2022. The Company's outstanding commitment under the loan to MPTC is to be paid in two installments of $11.4 million , one in fiscal year 2016, and one in fiscal year 2017. The interest on the loan accrues at 12% . In June 2016, the Company converted $17.0 million in deferred payment arrangements, previously recorded as long-term unbilled accounts receivable, with MPTC to a long-term note receivable due September 30, 2018. The note receivable carries an interest rate of 15% . In addition to the outstanding loans, the Company had $6.3 million and $28.6 million , as of July 1, 2016 and October 2, 2015 , respectively, in accounts receivable, which includes unbilled accounts receivable, from MPTC. CPTC Loans As of October 2, 2015 , the Company had loaned $73.5 million under a Tranche A loan and $10.4 million under a Tranche B loan to CPTC to fund the development, construction and initial operations of the Scripps Proton Therapy Center in San Diego, California under a loan agreement with ORIX and J.P. Morgan. ORIX is the loan agent for this facility and, along with CPTC and Scripps, has budgetary approval authority for the Scripps Proton Therapy Center. In November 2015, ORIX, J.P. Morgan and the Company (collectively the “Lenders”) and CPTC entered into a forbearance agreement whereby the lenders will not enforce their rights to principal and interest payments until April 2017, subject to CPTC maintaining certain covenants and achieving certain targets, with additional extensions through September 2017 based on hitting additional targets largely around patient volume and cash flow. In connection with the forbearance agreement the Lenders agreed to make available up to an additional $9.7 million of loan proceeds (based on their pro-rata share of the existing loan) with terms similar to the Tranche A loan for additional working capital needs; the Company's proportionate share of this commitment is $4.4 million ("Tranche C loan"). There were no other significant changes to the loan agreements. As of July 1, 2016 , the Company's remaining commitment under the Tranche C loan is expected to be drawn down over the next 12 months. The Tranche A, Tranche B and Tranche C loans are collectively, referred to as the “CPTC Loans.” As of July 1, 2016 , the Company had loaned $78.7 million under the Tranche A loan, $11.1 million under the Tranche B loan and $2.6 million under the Tranche C loan. No amounts were available for draw down under the Tranche A and Tranche B loans. The amounts loaned under the CPTC Loans include accrued interest. ORIX has the option to purchase the Company's share of the CPTC loans at par. The CPTC loans meet the definition of a debt security and therefore are accounted for as available-for-sale securities and recorded at fair value as of July 1, 2016 and October 2, 2015 . The Company's CPTC loans are included in other assets on the Company's Condensed Consolidated Balance Sheets as of July 1, 2016 and October 2, 2015 because the Company did not expect to be repaid and did not intend to sell all or a portion of its CPTC loans in the next twelve months. The Tranche B loan is subordinated to the Tranche A loan in the event of default, but otherwise has the same terms as the Tranche A loan. The CPTC Loans are collateralized by all of the assets of the Scripps Proton Therapy Center. The CPTC Loans mature in September 2017 and bear interest at the London Interbank Offer Rate (“LIBOR”) plus 7.00% per annum with a minimum interest rate of 9.00% per annum. Interest only payments on the CPTC Loans were due monthly in arrears until January 1, 2015, at which time monthly payments based on amortization of the principal balance over a 15 -year period at the above mentioned interest rate become due and payable. To date, no amortizing principal payments have been made. The principal and interest payments are subject to the forbearance agreement mentioned above. In addition to the outstanding loans, the Company had $30.9 million and $25.2 million , as of July 1, 2016 and October 2, 2015 , respectively, in accounts receivable, which includes unbilled accounts receivable, from CPTC. The Company has determined that MM Proton I, LLC, MPTC and CPTC are variable interest entities and that the Company holds a significant variable interest of each of the entities through its participation in the loan facilities and its agreements to supply and service the proton therapy equipment. The Company has concluded that it is not the primary beneficiary of any of these entities. The Company has no voting rights, has no approval authority or veto rights for these centers' budget, and does not have the power to direct patient recruitment, clinical operations and management of these Centers, which the Company believes are the matters that most significantly affect their economic performance. The Company’s exposure to loss as a result of its involvement with MM Proton I, LLC, MPTC and CPTC is limited to the carrying amounts of the above mentioned assets on its Condensed Consolidated Balance Sheets.

SEGMENT INFORMATION

SEGMENT INFORMATION	9 Months Ended
	Jul. 01, 2016
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION The Company’s operations are grouped into two reportable operating segments: Oncology Systems and Imaging Components. The Company’s Ginzton Technology Center ("GTC") and Varian Particle Therapy ("VPT") business are reflected in the “Other” category because these operating segments do not meet the criteria of a reportable operating segment. The operating segments were determined based on how the Company’s Chief Executive Officer, its Chief Operating Decision Maker (“CODM”), views and evaluates the Company’s operations. The CODM allocates resources to and evaluates the financial performance of each operating segment primarily based on operating earnings. Description of Segments The Oncology Systems segment designs, manufactures, sells and services hardware and software products for treating cancer with conventional radiation therapy, and advanced treatments such as fixed field intensity-modulated radiation therapy (“IMRT”), image-guided radiation therapy (“IGRT”), VMAT, stereotactic radiosurgery (“SRS”), stereotactic body radiotherapy (“SBRT”) and brachytherapy. Products include linear accelerators, brachytherapy afterloaders, treatment simulation and verification equipment and accessories; as well as information management, treatment planning and image processing software. Oncology Systems’ products enable radiation oncology departments in hospitals and clinics to perform conventional radiotherapy treatments and offer advanced treatments such as IMRT, IGRT, VMAT, SRS and SBRT, as well as to treat patients using brachytherapy techniques, which involve temporarily implanting radioactive sources. The Company’s Oncology Systems products are also used by neurosurgeons to perform stereotactic radiosurgery. Oncology Systems’ customers worldwide include university research and community hospitals, private and governmental institutions, healthcare agencies, physicians’ offices and cancer care clinics. The Imaging Components segment designs, manufactures, sells and services X-ray imaging components for use in a range of applications, including radiographic or fluoroscopic imaging, mammography, special procedures, computed tomography, computer-aided diagnostics and industrial applications. The Company provides a broad range of X-ray imaging components including X-ray tubes, flat panel digital image detectors, high voltage connectors, image processing software and workstations, ionization chambers and automatic exposure control systems. The Company’s X-ray imaging components are sold to imaging system OEM customers that incorporate them into their medical diagnostic, dental, veterinary and industrial imaging systems to independent service companies and directly to end-users for replacement purposes. The Imaging Components segment also designs, manufactures, sells and services security and inspection products, which include Linatron ® X-ray accelerators, imaging processing software and image detection products for security and inspection purposes, such as cargo screening at ports and borders and nondestructive examination in a variety of applications. The Company generally sells security and inspection products to OEM customers who incorporate its products into their inspection systems. The Company’s GTC and VPT business are reported together under the “Other” category. The VPT business develops, designs, manufactures, sells and services products and systems for delivering proton therapy, a form of external beam radiotherapy using proton beams for the treatment of cancer. GTC develops technologies that enhance the Company’s current businesses or may lead to new business areas, including technology to improve radiation therapy and X-ray imaging, as well as other technology for a variety of applications. The following table summarizes selected operating results information for each reportable segment: Three Months Ended Nine Months Ended (In millions) July 1, July 3, July 1, July 3, Revenues Oncology Systems $ 605.2 $ 558.7 $ 1,778.6 $ 1,711.4 Imaging Components 146.7 134.7 431.8 456.2 Total reportable segments 751.9 693.4 2,210.4 2,167.6 Other 37.5 90.6 94.9 113.7 Total Company $ 789.4 $ 784.0 $ 2,305.3 $ 2,281.3 Operating Earnings (Loss) Oncology Systems $ 142.5 $ 110.6 $ 387.2 $ 362.6 Imaging Components 28.2 23.2 79.1 104.4 Total reportable segments 170.7 133.8 466.3 467.0 Other (13.6 ) 9.8 (38.6 ) (16.5 ) Corporate (26.6 ) 0.6 (46.6 ) (30.8 ) Total Company $ 130.5 $ 144.2 $ 381.1 $ 419.7

SUMMARY OF SIGNIFICANT ACCOUN24

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Jul. 01, 2016
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the SEC. Certain information and note disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements and the accompanying notes are unaudited and should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended October 2, 2015 (the “ 2015 Annual Report”). In the opinion of management, the condensed consolidated financial statements herein include adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the Company’s financial position as of July 1, 2016 and October 2, 2015 , results of operations and statements of comprehensive earnings for the three and nine months ended July 1, 2016 and July 3, 2015 , and cash flows for the nine months ended July 1, 2016 and July 3, 2015 . The results of operations for the nine months ended July 1, 2016 are not necessarily indicative of the operating results to be expected for the full fiscal year or any future period.
Reclassifications	Reclassifications In the fiscal quarter ended July 1, 2016 , the Company began presenting all deferred tax assets and liabilities as noncurrent on its Condensed Consolidated Balance Sheets as discussed further in " Accounting Pronouncements Recently Adopted " below. In addition, certain reclassifications have been made to the amounts in the prior period to conform to the current period’s presentation.
Fiscal Year	Fiscal Year The fiscal years of the Company as reported are the 52- or 53-week periods ending on the Friday nearest September 30. Fiscal year 2016 is the 52-week period ending September 30, 2016 , and fiscal year 2015 was the 53-week period ended October 2, 2015 . The fiscal quarters ended July 1, 2016 and July 3, 2015 were both 13-week periods.
Principles of Consolidation	Principles of Consolidation The condensed consolidated financial statements include those of VMS and its wholly-owned and majority-owned or controlled subsidiaries. Intercompany balances, transactions and stock holdings have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Recent Accounting Pronouncements or Updates Not Yet Effective	Accounting Pronouncements Recently Adopted In November 2015, the Financial Accounting Standards Board ("FASB") issued an amendment to its accounting guidance related to balance sheet classification of deferred taxes. The amendment requires that deferred tax liabilities and assets be classified as noncurrent in the Condensed Consolidated Balance Sheets. The amendment is effective for all annual periods, and interim periods within those annual periods, beginning after December 15, 2016, with early adoption permitted. The Company has adopted this amendment in the fiscal quarter ended July 1, 2016 , on a retrospective basis. To conform to the current year presentation, the Company decreased current deferred tax assets by $132.1 million and current deferred tax liabilities, which was included in accrued liabilities, by $6.3 million and increased long-term deferred tax assets by $110.0 million and decreased deferred tax liabilities, which is included in other long-term liabilities, by $15.8 million , on its Condensed Consolidated Balance Sheet as of October 2, 2015 . The adoption of this amendment had no impact to the Company’s Condensed Consolidated Statements of Earnings or Statements of Cash Flows. Recent Accounting Pronouncements or Updates Not Yet Effective In June 2016, the FASB issued an amendment to its accounting guidance related to impairment of financial instruments. The amendment adds a new impairment model that is based on expected losses rather than incurred losses. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2021 with early adoption permitted beginning in the first quarter of fiscal year 2020. The Company is evaluating the impact of adopting this amendment to its consolidated financial statements. In March 2016, the FASB issued an amendment to its accounting guidance related to employee share-based payments. The amendment simplifies several aspects of the accounting for employee share-based payments including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2018 with early adoption permitted. The Company is evaluating the impact of adopting this amendment to its consolidated financial statements. In February 2016, the FASB issued a new standard on accounting for leases. The new standard is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet. The new standard will continue to classify leases as either finance or operating, with classification affecting the pattern of expense recognition in the statement of earnings. The new standard is required to be adopted using a modified retrospective method to each prior reporting period presented with various optional practical expedients. The new standard will be effective for the Company beginning in its first quarter of fiscal year 2020 with early adoption permitted. The Company is evaluating the impact of adopting this new standard to its consolidated financial statements. In January 2016, the FASB issued an amendment to its accounting guidance related to recognition and measurement of financial assets and financial liabilities. The amendment addresses certain aspects of recognition, measurement, presentation and disclosure of financial instruments. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2019. The Company is evaluating the impact of adopting this amendment to its consolidated financial statements. In September 2015, the FASB issued a new accounting standard that eliminates the requirement to restate prior period financial statements for measurement period adjustments following a business combination. The new standard will be effective for the Company beginning in its first quarter of fiscal year 2017. The new standard is not expected to have a material impact to the Company’s consolidated financial statements. In July 2015, the FASB issued an amendment to its accounting guidance related to inventory measurement. The amendment requires inventory measured using first-in, first-out (FIFO) or average cost to be subsequently measured at the lower of cost and net realizable value, thereby simplifying the current guidance that requires an entity to measure inventory at the lower of cost or market. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2018. The amendment is not expected to have a material impact to the Company’s consolidated financial statements. In April 2015, the FASB issued an amendment to its accounting guidance related to internal use software. The amendment clarifies that the software license element of a cloud computing arrangements should be accounted for consistent with the acquisition of other software licenses. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2017. The Company is evaluating the impact of adopting this amendment to its consolidated financial statements. In April 2015, the FASB issued an amendment to its accounting guidance related to retirement benefits. The amendment provides a practical expedient that permits an entity with a fiscal year-end that does not coincide with a month-end to measure defined benefit plan assets and obligations using the month-end that is closest to the entity’s fiscal year-end. The amendment also provides a practical expedient that permits an entity that has a significant event in an interim period to remeasure defined benefit plan assets and obligations using the month-end that is closest to the date of the significant event. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2017. The amendment is not expected to have a material impact to the Company’s consolidated financial statements. In March 2015, the FASB issued an amendment to its accounting guidance related to presentation of debt issuance costs. The amendment requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2017. In August 2015, the FASB further clarified that entities are permitted to defer and present debt issuance costs related to line-of-credit arrangements as assets. These amendments are not expected to have a material impact to the Company’s consolidated financial statements. In February 2015, the FASB issued an amendment to its accounting guidance related to consolidation. The amendment modifies the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2017. The amendment is not expected to have a material impact to the Company’s consolidated financial statements. In June 2014, the FASB issued an amendment to its accounting guidance related to stock-based compensation. The amendment requires that a performance target that could be achieved after the requisite service period be treated as a performance condition that affects vesting, rather than a condition that affects the grant-date fair value. The new guidance will be effective for the Company beginning in its first quarter of fiscal year 2017. The amendment is not expected to have a material impact to the Company's consolidated financial statements. In May 2014, the FASB issued a new revenue standard, which sets forth a single, comprehensive revenue recognition model for all contracts with customers to improve comparability. The new standard requires revenue recognition to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In March 2016, the FASB amended the principal-versus-agent implementation guidance and illustrations in the new standard. In April 2016, the FASB amended the guidance on identifying performance obligations and the implementation guidance on licensing in the new standard. In May 2016, the FASB amended the guidance on collectability, noncash consideration, presentation of sales tax and transition in the new standard. The new standard will be effective for the Company beginning in its first quarter of fiscal year 2019, with early adoption permitted, but not before the first quarter of fiscal year 2018. The new standard can be applied either retrospectively to each prior reporting period presented (i.e., full retrospective adoption) or with the cumulative effect of initially applying the update recognized at the date of the initial application (i.e., modified retrospective adoption) along with additional disclosures. The Company is evaluating the impact of adopting this standard to its consolidated financial statements.

BALANCE SHEET COMPONENTS (Table

BALANCE SHEET COMPONENTS (Tables)	9 Months Ended
	Jul. 01, 2016
Balance Sheet Components [Abstract]
Inventories:	The following table summarizes the Company's inventories: (In millions) July 1, October 2, Raw materials and parts $ 416.4 $ 348.3 Work-in-process 92.1 98.2 Finished goods 174.0 166.1 Total inventories $ 682.5 $ 612.6
Available-for-sale Securities:	The following tables summarize the Company's available-for-sale securities: July 1, 2016 (In millions) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Corporate debt securities: CPTC loans $ 92.4 $ — $ — $ 92.4 Total available-for-sale securities $ 92.4 $ — $ — $ 92.4 October 2, 2015 (In millions) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Corporate debt securities: CPTC loans $ 83.9 $ — $ — $ 83.9 Other 8.6 0.1 (0.3 ) 8.4 Non-U.S. government security 0.7 — — 0.7 Total available-for-sale securities $ 93.2 $ 0.1 $ (0.3 ) $ 93.0
Other long-term liabilities:	The following table summarizes the Company's other long-term liabilities: (In millions) July 1, October 2, Long-term income taxes payable $ 44.3 $ 44.5 Deferred tax liabilities 32.6 31.7 Other 62.7 62.0 Total other long-term liabilities $ 139.6 $ 138.2

FAIR VALUE (Tables)

FAIR VALUE (Tables)	9 Months Ended
	Jul. 01, 2016
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on Recurring Basis	In the tables below, the Company has segregated all assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date. Fair Value Measurement Using Quoted Prices in Significant Significant Total Type of Instruments (Level 1) (Level 2) (Level 3) Balance (In millions) Assets at July 1, 2016: Available-for-sale securities: Corporate debt securities $ — $ — $ 92.4 $ 92.4 Total assets measured at fair value $ — $ — $ 92.4 $ 92.4 Liabilities at July 1, 2016: Derivative liabilities $ — $ (0.2 ) $ — $ (0.2 ) Contingent consideration — — (1.0 ) (1.0 ) Total liabilities measured at fair value $ — $ (0.2 ) $ (1.0 ) $ (1.2 ) Assets at October 2, 2015: Available-for-sale securities: Corporate debt securities $ — $ 8.4 $ 83.9 $ 92.3 Non-U.S. government security — 0.7 — 0.7 Total assets measured at fair value $ — $ 9.1 $ 83.9 $ 93.0 Liabilities at October 2, 2015: Contingent consideration $ — $ — $ (4.1 ) $ (4.1 ) Total liabilities measured at fair value $ — $ — $ (4.1 ) $ (4.1 )
Reconciliation for Assets Measured and Recorded at Fair Value on Recurring Basis	The following table presents the reconciliation for all assets and liabilities measured and recorded at fair value on a recurring basis using significant unobservable inputs (Level 3): (In millions) CPTC Loans Contingent Balance at October 2, 2015 $ 83.9 $ (4.1 ) Additions (1) 8.5 — Settlements (2) — 3.5 Change in fair value recognized in earnings — (0.4 ) Balance at July 1, 2016 $ 92.4 $ (1.0 ) (1) Amounts reported under CPTC loans represent draw downs and accrued interest. (2) Amounts reported under Contingent Consideration represent cash payments to settle contingent consideration liabilities.
Reconciliation for Liabilities Measured and Recorded at Fair Value on Recurring Basis	The following table presents the reconciliation for all assets and liabilities measured and recorded at fair value on a recurring basis using significant unobservable inputs (Level 3): (In millions) CPTC Loans Contingent Balance at October 2, 2015 $ 83.9 $ (4.1 ) Additions (1) 8.5 — Settlements (2) — 3.5 Change in fair value recognized in earnings — (0.4 ) Balance at July 1, 2016 $ 92.4 $ (1.0 ) (1) Amounts reported under CPTC loans represent draw downs and accrued interest. (2) Amounts reported under Contingent Consideration represent cash payments to settle contingent consideration liabilities.

RECEIVABLES (Tables)

RECEIVABLES (Tables)	9 Months Ended
	Jul. 01, 2016
Receivables [Abstract]
Schedule of Accounts, Notes, Loans and Financing Receivable	The following table summarizes the Company's accounts receivable and notes receivable as of July 1, 2016 and October 2, 2015 : (In millions) July 1, October 2, Accounts receivable, gross $ 915.5 $ 838.2 Allowance for doubtful accounts (25.6 ) (21.2 ) Accounts receivable, net $ 889.9 $ 817.0 Short-term $ 840.4 $ 770.9 Long-term (1) $ 49.5 $ 46.1 Notes receivable $ 53.6 $ 40.9 Short-term (2) $ 5.8 $ 10.0 Long-term (1) $ 47.8 $ 30.9 (1) Included in other assets on the Company's Condensed Consolidated Balance Sheets. (2) Included in prepaid expenses and other current assets on the Company's Condensed Consolidated Balance Sheets.

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS (Tables)	9 Months Ended
	Jul. 01, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Activity of Goodwill by Reportable Operating Segment	The following table reflects the activity of goodwill by reportable operating segment: (In millions) Oncology Systems Imaging Components Other Total Balance at October 2, 2015 $ 158.8 $ 74.7 $ 50.0 $ 283.5 Foreign currency translation adjustments — — (0.6 ) (0.6 ) Balance at July 1, 2016 $ 158.8 $ 74.7 $ 49.4 $ 282.9
Gross Carrying Amount and Accumulated Amortization of Intangible Assets	The following table reflects the gross carrying amount and accumulated amortization of the Company’s finite-lived intangible assets included in other assets on the Condensed Consolidated Balance Sheets: (In millions) July 1, October 2, Acquired existing technology $ 86.4 $ 71.7 Patents, licenses and other 35.3 35.3 Customer contracts and supplier relationship 20.7 20.1 Accumulated amortization (74.7 ) (65.1 ) Net carrying amount $ 67.7 $ 62.0

BORROWINGS (Tables)

BORROWINGS (Tables)	9 Months Ended
	Jul. 01, 2016
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	The following table summarizes the Company's short-term and long-term debt: July 1, 2016 October 2, 2015 (Dollars in millions) Amount Weighted-Average Interest Rate Amount Weighted-Average Interest Rate Short-term debt: Current maturities of 2013 Term Loan Facility $ 50.0 1.59 % $ 50.0 1.32 % 2013 Revolving Credit Facility 330.0 1.83 % 90.0 1.57 % Sumitomo Credit Facility 21.4 0.53 % 18.4 0.63 % Total short-term debt $ 401.4 $ 158.4 Long-term debt: 2013 Term Loan Facility $ 300.0 1.59 % $ 337.5 1.32 % Total long-term debt $ 300.0 $ 337.5
Schedule of Short-term Debt	The following table summarizes the Company's short-term and long-term debt: July 1, 2016 October 2, 2015 (Dollars in millions) Amount Weighted-Average Interest Rate Amount Weighted-Average Interest Rate Short-term debt: Current maturities of 2013 Term Loan Facility $ 50.0 1.59 % $ 50.0 1.32 % 2013 Revolving Credit Facility 330.0 1.83 % 90.0 1.57 % Sumitomo Credit Facility 21.4 0.53 % 18.4 0.63 % Total short-term debt $ 401.4 $ 158.4 Long-term debt: 2013 Term Loan Facility $ 300.0 1.59 % $ 337.5 1.32 % Total long-term debt $ 300.0 $ 337.5

DERIVATIVE INSTRUMENTS AND HE30

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)	9 Months Ended
	Jul. 01, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair Value of Derivative Instruments Reported in Condensed Consolidated Balance Sheets	The fair values of derivative instruments reported on the Company’s Condensed Consolidated Balance Sheets were as follows: Liability Derivatives Balance Sheet July 1, October 2, (In millions) Location Fair Value Fair Value Derivatives designated as hedging instruments: Foreign exchange forward contracts Accrued liabilities $ 0.2 $ — Total derivatives $ 0.2 $ —
Outstanding Foreign Currency Forward Contracts	The Company had the following outstanding foreign currency forward contracts that were entered into to hedge balance sheet exposures from its various foreign subsidiaries and business units: July 1, 2016 (In millions) Notional Notional Australian Dollar $ 18.8 $ — Brazilian Real 9.0 — British Pound 66.2 — Canadian Dollar — 4.8 Euro 184.9 9.0 Hungarian Forint 3.5 — Indian Rupee 12.7 — Japanese Yen 82.7 — New Zealand Dollar 1.5 — Swedish Krona 1.8 — Swiss Franc — 82.6 Thai Baht 4.4 — Totals $ 385.5 $ 96.4 The Company had the following outstanding foreign currency forward contracts that were entered into to hedge forecasted revenues and designated as cash flow hedges: July 1, 2016 (In millions) Notional Euro $ 16.5 Totals $ 16.5
Effective Portion of Foreign Currency Forward Contracts Designated as Cash Flow Hedges	The following table presents the amounts, before tax, recognized in accumulated other comprehensive loss on the Condensed Consolidated Balance Sheets and in the Condensed Consolidated Statements of Earnings that are related to the effective portion of the foreign currency forward contracts designated as cash flow hedges: Gain (Loss) Recognized in Other Comprehensive Income (Effective Portion) Location of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Net Earnings (Effective Portion) Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Net Earnings (Effective Portion) Three Months Ended Nine Months Ended Three Months Ended Nine Months Ended (In millions) July 1, July 3, July 1, July 3, July 1, July 3, July 1, July 3, Foreign currency forward contracts $ 0.4 $ 0.3 $ (0.9 ) $ 2.3 Revenues $ (0.7 ) $ 0.7 $ (0.6 ) $ 3.4
Gains (Losses) Related to Foreign Currency Forward Exchange Contracts that are Not Designated as Hedging Instruments	The following table presents the gains recognized in the Condensed Consolidated Statements of Earnings related to the foreign currency forward exchange contracts that are not designated as hedging instruments: Location of Gain (Loss) Recognized in Income on Derivative Instruments Amount of Gain (Loss) Recognized in Net Earnings on Derivative Instruments Three Months Ended Nine Months Ended (In millions) July 1, July 3, July 1, July 3, Selling, general and administrative expenses $ 1.5 $ (1.3 ) $ (3.4 ) $ 32.7

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended
	Jul. 01, 2016
Commitments and Contingencies Disclosure [Abstract]
Accrued Product Warranty	The following table reflects the changes in the Company’s accrued product warranty: Nine Months Ended July 1, July 3, (In millions) 2016 2015 Accrued product warranty, at beginning of period $ 45.9 $ 49.3 Charged to cost of revenues 39.6 33.1 Actual product warranty expenditures (35.5 ) (38.8 ) Accrued product warranty, at end of period $ 50.0 $ 43.6

RETIREMENT PLANS (Tables)

RETIREMENT PLANS (Tables)	9 Months Ended
	Jul. 01, 2016
Compensation and Retirement Disclosure [Abstract]
Schedule of Net Periodic Benefit Costs	The components of net defined benefit costs were as follows: Three Months Ended Nine Months Ended (In millions) July 1, July 3, July 1, July 3, Defined Benefit Plans Service cost $ 1.5 $ 1.2 $ 4.5 $ 3.6 Interest cost 1.0 1.3 3.0 3.9 Expected return on plan assets (1.7 ) (1.8 ) (5.1 ) (5.4 ) Amortization of prior service cost — — — 0.1 Recognized actuarial loss 0.7 0.6 2.2 1.8 Net periodic benefit cost $ 1.5 $ 1.3 $ 4.6 $ 4.0

STOCKHOLDERS' EQUITY AND NONC33

STOCKHOLDERS' EQUITY AND NONCONTROLLING INTERESTS (Tables)	9 Months Ended
	Jul. 01, 2016
Equity [Abstract]
Schedule of Share Repurchases	The Company repurchased shares of VMS common stock under various authorizations during the periods presented as follows: Three Months Ended Nine Months Ended (In thousands, except per share amounts) July 1, July 3, July 1, July 3, Number of shares 1,500 1,000 4,650 3,325 Average repurchase price per share $ 83.68 $ 92.39 $ 80.48 $ 88.30 Total cost $ 125,513 $ 92,389 $ 374,217 $ 293,570 Included in the table above, VMS repurchased common stock under various ASR agreements during the periods presented as follows: Three Months Ended Nine Months Ended (In thousands, except per share amounts) July 1, July 3, July 1, July 3, Number of shares — 744 519 1,239 Average repurchase price per share $ — $ 94.10 $ 77.81 $ 92.84 Total cost $ — $ 70,000 $ 40,400 $ 115,000
Schedule of Accumulated Other Comprehensive Earnings (Loss) and Related Tax Effects	The changes in accumulated other comprehensive loss by component and related tax effects are summarized as follows: (In thousands) Net Unrealized Gains Net Net Cumulative Accumulated Balance at October 2, 2015 $ (46,070 ) $ — $ (112 ) $ (40,281 ) $ (86,463 ) Other comprehensive earnings (loss) before reclassifications — (917 ) (440 ) 906 (451 ) Amounts reclassified out of other comprehensive earnings 1,849 589 604 — 3,042 Tax benefit (expense) (260 ) 122 (52 ) — (190 ) Balance at July 1, 2016 $ (44,481 ) $ (206 ) $ — $ (39,375 ) $ (84,062 ) (In thousands) Net Unrealized Gain Net Net Cumulative Accumulated Balance at September 26, 2014 $ (44,060 ) $ 965 $ — $ (15,516 ) $ (58,611 ) Other comprehensive earnings (loss) before reclassifications — 2,318 (320 ) (28,348 ) (26,350 ) Amounts reclassified out of other comprehensive earnings 1,623 (3,441 ) — (1,818 ) Tax benefit (expense) (226 ) 420 102 — 296 Balance at July 3, 2015 $ (42,663 ) $ 262 $ (218 ) $ (43,864 ) $ (86,483 )
Schedule of Amounts Reclassified Out of Other Comprehensive Earnings	The amounts reclassified out of other comprehensive earnings into the Condensed Consolidated Statements of Earnings, with line item location, during each period were as follows: Three Months Ended Nine Months Ended July 1, July 3, July 1, July 3, (In thousands) 2016 2015 2016 2015 Comprehensive Earnings Components Income (Loss) Before Taxes Income (Loss) Before Taxes Line Item in Statements of Earnings Unrealized loss on defined benefit pension and post-retirement benefit plans $ (617 ) $ (541 ) $ (1,849 ) $ (1,623 ) Cost of revenues & Operating expenses Unrealized gain (loss) on cash flow hedging instruments (668 ) 693 (589 ) 3,441 Revenues Unrealized loss on available-for-sale-investments — — (604 ) — Operating expenses Total amounts reclassified out of other comprehensive earnings $ (1,285 ) $ 152 $ (3,042 ) $ 1,818
Schedule of Changes In Noncontrolling Interests	Changes in noncontrolling interests and redeemable noncontrolling interests relating to MeVis and other subsidiaries of the Company were as follows: Nine Months Ended Nine Months Ended July 1, 2016 July 3, 2015 (In thousands) Noncontrolling Interests Redeemable Noncontrolling Interests Noncontrolling Interests Redeemable Noncontrolling Interests Balance at beginning of period $ 14,744 $ — $ — $ — Net earnings (loss) attributable to noncontrolling interests (216 ) 334 136 — Acquisition of Mevis — — 10,218 Capital contribution from noncontrolling interest holders — — 3,993 — Reclassification of noncontrolling interests in MeVis to redeemable noncontrolling interests (10,382 ) 10,382 — — Other (499 ) (385 ) 21 — Balance at end of period $ 3,647 $ 10,331 $ 14,368 $ —

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	9 Months Ended
	Jul. 01, 2016
Earnings Per Share [Abstract]
Computation of Net Basic and Diluted Earnings Per Share	The following table sets forth the computation of basic and diluted net earnings per share: Three Months Ended Nine Months Ended (In thousands, except per share amounts) July 1, July 3, July 1, July 3, Net earnings attributable to Varian $ 98,795 $ 113,506 $ 284,793 $ 312,789 Weighted average shares outstanding - basic 94,940 99,721 95,955 100,090 Dilutive effect of potential common shares 492 733 567 930 Weighted average shares outstanding - diluted 95,432 100,454 96,522 101,020 Net earnings per share attributable to Varian - basic $ 1.04 $ 1.14 $ 2.97 $ 3.13 Net earnings per share attributable to Varian - diluted $ 1.04 $ 1.13 $ 2.95 $ 3.10 Anti-dilutive employee shared based awards, excluded 2,014 948 2,016 994

EMPLOYEE STOCK PLANS (Tables)

EMPLOYEE STOCK PLANS (Tables)	9 Months Ended
	Jul. 01, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Net Share-Based Compensation Expense	The table below summarizes the net share-based compensation expense recognized for employee stock awards and for the option component of the employee stock purchase plan shares: Three Months Ended Nine Months Ended (In thousands) July 1, July 3, July 1, July 3, Cost of revenues - Product $ 1,033 $ 1,263 $ 3,141 $ 3,578 Cost of revenues - Service 1,114 1,066 3,063 3,004 Research and development 1,723 1,717 5,046 5,109 Selling, general and administrative 8,346 7,310 24,771 24,903 Total share-based compensation expense $ 12,216 $ 11,356 $ 36,021 $ 36,594 Income tax benefit for share-based compensation $ (3,701 ) $ (3,455 ) $ (10,958 ) $ (11,371 )
Fair Value of Employee Stock Option Plans With Weighted Average Assumptions	The fair value of options granted was estimated at the date of grant using the Black-Scholes model with the following weighted average assumptions: Three Months Ended Nine Months Ended July 1, July 3, July 1, July 3, Employee Stock Option Plans Expected term (in years) 4.13 4.13 4.13 4.15 Risk-free interest rate 1.2 % 1.3 % 1.1 % 1.3 % Expected volatility 20.5 % 21.6 % 20.1 % 22.1 % Expected dividend — % — % — % — % Weighted average fair value at grant date $ 15.29 $ 17.16 $ 13.71 $ 18.52
Fair Value of Employee Stock Purchase Plan With Weighted Average Assumptions	The option component of employee stock purchase plan shares was estimated at the date of grant using the Black-Scholes model with the following weighted average assumptions: Three Months Ended Nine Months Ended July 1, July 3, July 1, July 3, Employee Stock Purchase Plan Expected term (in years) 0.50 0.50 0.50 0.50 Risk-free interest rate 0.4 % 0.1 % 0.3 % 0.1 % Expected volatility 18.3 % 17.2 % 17.6 % 12.7 % Expected dividend — % — % — % — % Weighted average fair value at grant date $ 16.60 $ 17.56 $ 16.09 $ 15.87
Summary of Share-Based Awards Available for Grant	A summary of share-based awards available for grant is as follows: (In thousands) Shares Available for Grant Balance at October 2, 2015 6,661 Granted (2,327 ) Cancelled or expired 277 Balance at July 1, 2016 4,611
Activity Under Employee Stock Plans	Activity under the Company’s employee stock plans is presented below: Options Outstanding (In thousands, except per share amounts) Number of Weighted Weighted Aggregate Balance at October 2, 2015 2,537 $ 72.58 Granted 828 75.97 Cancelled or expired (23 ) 85.95 Exercised (377 ) 52.02 Balance at July 1, 2016 2,965 $ 76.03 4.6 $ 26,060 Exercisable at July 1, 2016 1,664 $ 72.13 3.4 $ 20,556 (1) The aggregate intrinsic value represents the total pre-tax intrinsic value of options, which is computed based on the difference between the exercise price and VMS’s closing common stock price of $82.60 as of July 1, 2016 , the last trading date of the third quarter of fiscal year 2016 , and which would have been received by the option holders had all option holders exercised and sold their options as of that date.
Activity for Restricted Stock, Restricted Stock Units, Deferred Stock Units and Performance Units	The activity for restricted stock, restricted stock units, deferred stock units and performance units is summarized as follows: (In thousands, except per share amounts) Number of Weighted Average Balance at October 2, 2015 950 $ 84.11 Granted 485 77.89 Vested (389 ) 80.98 Cancelled or expired (75 ) 81.86 Balance at April 1, 2016 971 $ 82.36

VPT LOANS (Tables)

VPT LOANS (Tables)	9 Months Ended
	Jul. 01, 2016
Receivables [Abstract]
Schedule Of Loans and Commitments to Fund PT Centers	The following table lists the Company's outstanding loans and commitments for funding development and construction of various proton therapy centers: July 1, 2016 October 2, 2015 (In millions) Balance Commitment Balance Commitment Long-term notes receivable (1) : NYPC loan $ 18.5 $ — $ 18.7 $ 72.8 MPTC loans (2) 29.3 22.8 12.2 22.8 $ 47.8 $ 22.8 $ 30.9 $ 95.6 Available-for-sale Securities (1) : CPTC loans $ 92.4 $ 1.9 $ 83.9 $ — $ 92.4 $ 1.9 $ 83.9 $ — (1) Included in other assets on the Company's Condensed Consolidated Balance Sheets. (2) Increase in balance was primarily due to a $17.0 million conversion from long-term unbilled accounts receivable to long-term notes receivable.

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	9 Months Ended
	Jul. 01, 2016
Segment Reporting [Abstract]
Operating Results Information for Each Business Segment	The following table summarizes selected operating results information for each reportable segment: Three Months Ended Nine Months Ended (In millions) July 1, July 3, July 1, July 3, Revenues Oncology Systems $ 605.2 $ 558.7 $ 1,778.6 $ 1,711.4 Imaging Components 146.7 134.7 431.8 456.2 Total reportable segments 751.9 693.4 2,210.4 2,167.6 Other 37.5 90.6 94.9 113.7 Total Company $ 789.4 $ 784.0 $ 2,305.3 $ 2,281.3 Operating Earnings (Loss) Oncology Systems $ 142.5 $ 110.6 $ 387.2 $ 362.6 Imaging Components 28.2 23.2 79.1 104.4 Total reportable segments 170.7 133.8 466.3 467.0 Other (13.6 ) 9.8 (38.6 ) (16.5 ) Corporate (26.6 ) 0.6 (46.6 ) (30.8 ) Total Company $ 130.5 $ 144.2 $ 381.1 $ 419.7

SUMMARY OF SIGNIFICANT ACCOUN38

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Narrative (Details) - New Accounting Pronouncement, Early Adoption, Effect $ in Millions	Oct. 02, 2015USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred tax assets, current - increase (decrease)	$ (132.1)
Deferred tax liabilities, current - increase (decrease)	(6.3)
Deferred tax liabilities - increase (decrease)	110
Deferred tax assets - increase (decrease)	$ (15.8)

BALANCE SHEET COMPONENTS - Comp

BALANCE SHEET COMPONENTS - Components of Inventories (Detail) - USD ($) $ in Thousands	Jul. 01, 2016	Oct. 02, 2015
Balance Sheet Components [Abstract]
Raw materials and parts	$ 416,400	$ 348,300
Work-in-process	92,100	98,200
Finished goods	174,000	166,100
Total inventories	$ 682,490	$ 612,607	[1]
[1]	The condensed consolidated balance sheet as of October 2, 2015 was derived from audited financial statements as of that date, but does not include all disclosures required by accounting principles generally accepted in the United States of America.

BALANCE SHEET COMPONENTS - Avai

BALANCE SHEET COMPONENTS - Available-for-Sale Securities (Detail) - USD ($) $ in Millions	Jul. 01, 2016	Oct. 02, 2015
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 92.4	$ 93.2
Gross Unrealized Gains	0	0.1
Gross Unrealized Losses	0	(0.3)
Fair Value	92.4	93
CPTC loans
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	92.4	83.9
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	$ 92.4	83.9
Other
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		8.6
Gross Unrealized Gains		0.1
Gross Unrealized Losses		(0.3)
Fair Value		8.4
Non-U.S. government security
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		0.7
Gross Unrealized Gains		0
Gross Unrealized Losses		0
Fair Value		$ 0.7

BALANCE SHEET COMPONENTS - Co41

BALANCE SHEET COMPONENTS - Components of Other Long-Term Liabilities (Detail) - USD ($) $ in Thousands	Jul. 01, 2016	Oct. 02, 2015
Balance Sheet Components [Abstract]
Long-term income taxes payable	$ 44,300	$ 44,500
Deferred tax liabilities	32,600	31,700
Other	62,700	62,000
Total other long-term liabilities	$ 139,554	$ 138,235	[1]
[1]	The condensed consolidated balance sheet as of October 2, 2015 was derived from audited financial statements as of that date, but does not include all disclosures required by accounting principles generally accepted in the United States of America.

FAIR VALUE - Assets and Liabili

FAIR VALUE - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Millions	Jul. 01, 2016	Oct. 02, 2015
Assets/Liabilities Measured at Fair Value on a Recurring Basis
Available-for-sale securities:	$ 92.4	$ 93
Non-U.S. government security
Assets/Liabilities Measured at Fair Value on a Recurring Basis
Available-for-sale securities:		0.7
Fair Value, Measurements, Recurring
Assets/Liabilities Measured at Fair Value on a Recurring Basis
Total assets measured at fair value	92.4	93
Derivative liabilities	(0.2)
Contingent consideration	(1)	(4.1)
Total liabilities measured at fair value	(1.2)	(4.1)
Fair Value, Measurements, Recurring | Corporate debt securities
Assets/Liabilities Measured at Fair Value on a Recurring Basis
Available-for-sale securities:	92.4	92.3
Fair Value, Measurements, Recurring | Non-U.S. government security
Assets/Liabilities Measured at Fair Value on a Recurring Basis
Available-for-sale securities:		0.7
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Instruments
Assets/Liabilities Measured at Fair Value on a Recurring Basis
Total assets measured at fair value	0	0
Derivative liabilities	0
Contingent consideration	0	0
Total liabilities measured at fair value	0	0
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Instruments | Corporate debt securities
Assets/Liabilities Measured at Fair Value on a Recurring Basis
Available-for-sale securities:	0	0
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Instruments | Non-U.S. government security
Assets/Liabilities Measured at Fair Value on a Recurring Basis
Available-for-sale securities:		0
Fair Value, Measurements, Recurring | Significant Other Observable Inputs
Assets/Liabilities Measured at Fair Value on a Recurring Basis
Total assets measured at fair value	0	9.1
Derivative liabilities	(0.2)
Contingent consideration	0	0
Total liabilities measured at fair value	(0.2)	0
Fair Value, Measurements, Recurring | Significant Other Observable Inputs | Corporate debt securities
Assets/Liabilities Measured at Fair Value on a Recurring Basis
Available-for-sale securities:	0	8.4
Fair Value, Measurements, Recurring | Significant Other Observable Inputs | Non-U.S. government security
Assets/Liabilities Measured at Fair Value on a Recurring Basis
Available-for-sale securities:		0.7
Fair Value, Measurements, Recurring | Significant Unobservable Inputs
Assets/Liabilities Measured at Fair Value on a Recurring Basis
Total assets measured at fair value	92.4	83.9
Derivative liabilities	0
Contingent consideration	(1)	(4.1)
Total liabilities measured at fair value	(1)	(4.1)
Fair Value, Measurements, Recurring | Significant Unobservable Inputs | Corporate debt securities
Assets/Liabilities Measured at Fair Value on a Recurring Basis
Available-for-sale securities:	$ 92.4	83.9
Fair Value, Measurements, Recurring | Significant Unobservable Inputs | Non-U.S. government security
Assets/Liabilities Measured at Fair Value on a Recurring Basis
Available-for-sale securities:		$ 0

FAIR VALUE - Reconciliation for

FAIR VALUE - Reconciliation for Assets and Liabilities Measured and Recorded at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring $ in Millions	9 Months Ended
	Jul. 01, 2016USD ($)
CPTC Loans
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 83.9
Additions	8.5
Settlements	0
Change in fair value recognized in earnings	0
Ending balance	92.4
Contingent Consideration
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	(4.1)
Additions	0
Settlements	3.5
Change in fair value recognized in earnings	(0.4)
Ending balance	$ (1)

FAIR VALUE - Additional Informa

FAIR VALUE - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended
	Jul. 01, 2016	Oct. 02, 2015
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Minimum remaining maturity of derivatives (in months)	1 month
Maximum remaining maturity of derivatives (in months)	13 months
Fair value of current maturities of long-term debt	$ 50,000	$ 50,000	[1]
Long-term debt	300,000	337,500	[1]
Notes Receivable
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Long-term	47,800	30,900
2013 Term Loan Facility
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Long-term debt	300,000	337,500
2013 Term Loan Facility
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value of current maturities of long-term debt	$ 50,000	$ 50,000
[1]	The condensed consolidated balance sheet as of October 2, 2015 was derived from audited financial statements as of that date, but does not include all disclosures required by accounting principles generally accepted in the United States of America.

RECEIVABLES (Details)

RECEIVABLES (Details) - USD ($) $ in Thousands	Jul. 01, 2016	Oct. 02, 2015
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 915,500	$ 838,200
Allowance for doubtful accounts	(25,600)	(21,200)
Accounts receivable, net	889,900	817,000
Short-term	840,437	770,920	[1]
Long-term	49,500	46,100
Notes Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes receivable	53,600	40,900
Short-term	5,800	10,000
Long-term	$ 47,800	$ 30,900
[1]	The condensed consolidated balance sheet as of October 2, 2015 was derived from audited financial statements as of that date, but does not include all disclosures required by accounting principles generally accepted in the United States of America.

GOODWILL AND INTANGIBLE ASSET46

GOODWILL AND INTANGIBLE ASSETS - Activity of Goodwill by Reportable Operating Segment (Detail) $ in Thousands	9 Months Ended
	Jul. 01, 2016USD ($)
Goodwill [Roll Forward]
Balance, beginning	$ 283,452	[1]
Foreign currency translation adjustments	(600)
Balance, ending	282,894
Oncology Systems
Goodwill [Roll Forward]
Balance, beginning	158,800
Foreign currency translation adjustments	0
Balance, ending	158,800
Imaging Components
Goodwill [Roll Forward]
Balance, beginning	74,700
Foreign currency translation adjustments	0
Balance, ending	74,700
Other
Goodwill [Roll Forward]
Balance, beginning	50,000
Foreign currency translation adjustments	(600)
Balance, ending	$ 49,400
[1]	The condensed consolidated balance sheet as of October 2, 2015 was derived from audited financial statements as of that date, but does not include all disclosures required by accounting principles generally accepted in the United States of America.

GOODWILL AND INTANGIBLE ASSET47

GOODWILL AND INTANGIBLE ASSETS - Gross Carrying Amount and Accumulated Amortization of Intangible Assets (Detail) - USD ($) $ in Millions	Jul. 01, 2016	Oct. 02, 2015
Finite Lived Intangible Assets [Line Items]
Accumulated amortization	$ (74.7)	$ (65.1)
Net carrying amount	67.7	62
Acquired existing technology
Finite Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	86.4	71.7
Patents, licenses and other
Finite Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	35.3	35.3
Customer contracts and supplier relationship
Finite Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	$ 20.7	$ 20.1

GOODWILL AND INTANGIBLE ASSET48

GOODWILL AND INTANGIBLE ASSETS - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jul. 01, 2016	Jul. 03, 2015	Jul. 01, 2016	Jul. 03, 2015	Oct. 02, 2015
Indefinite-lived Intangible Assets [Line Items]
Amortization expense for intangible assets	$ 2,900	$ 1,800	$ 9,662	$ 5,112
Future amortization expense, fiscal year 2016	4,000		4,000
Future amortization expense, fiscal year 2017	15,200		15,200
Future amortization expense, fiscal year 2018	11,600		11,600
Future amortization expense, fiscal year 2019	10,800		10,800
Future amortization expense, fiscal year 2020	9,500		9,500
Future amortization expense, thereafter	16,600		16,600
In Process Research and Development
Indefinite-lived Intangible Assets [Line Items]
Research and development asset acquired fair value	$ 8,800		$ 8,800		$ 10,600

RELATED PARTY TRANSACTIONS - Ad

RELATED PARTY TRANSACTIONS - Additional Information (Detail) - dpiX Holding - Affiliated Entity $ in Millions	3 Months Ended		9 Months Ended
	Jul. 01, 2016USD ($)member	Jul. 03, 2015USD ($)	Jul. 01, 2016USD ($)member	Jul. 03, 2015USD ($)	Oct. 02, 2015USD ($)
Related Party Transaction [Line Items]
Ownership interest in dpiX Holding LLC (as a percent)	40.00%		40.00%
Number of members | member	2		2
dpiX Holding LLC's ownership interest in dpiX LLC (as a percent)	100.00%		100.00%
Income (Loss) on equity investment in affiliate	$ (0.8)		$ (0.9)	$ 0.5
Carrying value of the equity investment in dpiX Holding	47.8		47.8		$ 47.3
Purchases of glass transistor arrays from dpiX	6.4	$ 5.6	$ 16.8	$ 15.5
Percentage of manufacturing capacity			50.00%
Percentage of fixed costs			50.00%
Fixed cost commitments	$ 9		$ 9

BORROWINGS - Schedule of Debt (

BORROWINGS - Schedule of Debt (Details) - USD ($) $ in Thousands	Jul. 01, 2016	Oct. 02, 2015
Debt Instrument [Line Items]
Current maturities of long-term debt	$ 50,000	$ 50,000	[1]
Short-term borrowings	351,441	108,446	[1]
Total short-term debt	401,400	158,400
Long-term debt	$ 300,000	$ 337,500	[1]
2013 Term Loan Facility
Debt Instrument [Line Items]
Weighted-Average Interest Rate (as a percent)	1.59%	1.32%
Long-term debt	$ 300,000	$ 337,500
2013 Term Loan Facility
Debt Instrument [Line Items]
Current maturities of long-term debt	$ 50,000	$ 50,000
Weighted-Average Interest Rate (as a percent)	1.59%	1.32%
2013 Revolving Credit Facility
Debt Instrument [Line Items]
Weighted-Average Interest Rate (as a percent)	1.83%	1.57%
Short-term borrowings	$ 330,000	$ 90,000
Sumitomo Credit Facility
Debt Instrument [Line Items]
Weighted-Average Interest Rate (as a percent)	0.53%	0.63%
Short-term borrowings	$ 21,400	$ 18,400
[1]	The condensed consolidated balance sheet as of October 2, 2015 was derived from audited financial statements as of that date, but does not include all disclosures required by accounting principles generally accepted in the United States of America.

BORROWINGS - Additional Informa

BORROWINGS - Additional Information (Detail)	9 Months Ended
	Jul. 01, 2016JPY (¥)	Jul. 01, 2016USD ($)	Nov. 30, 2015USD ($)	Aug. 27, 2013USD ($)
Amended 2013 Credit Facility | 2013 Revolving Credit Facility
Line Of Credit Facility [Line Items]
Credit facility term (in years)	5 years
Loan facility, maximum borrowing capacity		$ 500,000,000	$ 500,000,000	$ 300,000,000
Amended 2013 Credit Facility | 2013 Revolving Credit Facility | Minimum
Line Of Credit Facility [Line Items]
Expiration period (in months)	30 days
Amended 2013 Credit Facility | 2013 Revolving Credit Facility | Letter of Credit
Line Of Credit Facility [Line Items]
Loan facility, maximum borrowing capacity		50,000,000
Amended 2013 Credit Facility | 2013 Revolving Credit Facility | Swing Line Loans
Line Of Credit Facility [Line Items]
Loan facility, maximum borrowing capacity		25,000,000
Amended 2013 Credit Facility | 2013 Term Loan Facility
Line Of Credit Facility [Line Items]
Credit facility term (in years)	5 years
Loan facility, maximum borrowing capacity		$ 500,000,000
Amended 2013 Credit Facility | Eurodollar | 2013 Revolving Credit Facility | Minimum
Line Of Credit Facility [Line Items]
Line of credit, interest rate (as a percent)	1.125%
Amended 2013 Credit Facility | Eurodollar | 2013 Revolving Credit Facility | Maximum
Line Of Credit Facility [Line Items]
Line of credit, interest rate (as a percent)	1.375%
Amended 2013 Credit Facility | Eurodollar | 2013 Term Loan Facility | Minimum
Line Of Credit Facility [Line Items]
Line of credit, interest rate (as a percent)	0.875%
Amended 2013 Credit Facility | Eurodollar | 2013 Term Loan Facility | Maximum
Line Of Credit Facility [Line Items]
Line of credit, interest rate (as a percent)	1.125%
Amended 2013 Credit Facility | Federal Funds Effective Swap Rate | 2013 Revolving Credit Facility
Line Of Credit Facility [Line Items]
Line of credit, interest rate (as a percent)	0.50%
Amended 2013 Credit Facility | Federal Funds Effective Swap Rate | 2013 Term Loan Facility
Line Of Credit Facility [Line Items]
Line of credit, interest rate (as a percent)	0.50%
Amended 2013 Credit Facility | Eurodollar1 | 2013 Revolving Credit Facility
Line Of Credit Facility [Line Items]
Percentage added to Eurodollar base rate before margin (as a percent)	1.00%
Amended 2013 Credit Facility | Eurodollar1 | 2013 Revolving Credit Facility | Minimum
Line Of Credit Facility [Line Items]
Line of credit, interest rate (as a percent)	0.125%
Amended 2013 Credit Facility | Eurodollar1 | 2013 Revolving Credit Facility | Maximum
Line Of Credit Facility [Line Items]
Line of credit, interest rate (as a percent)	0.375%
Amended 2013 Credit Facility | Eurodollar1 | 2013 Term Loan Facility
Line Of Credit Facility [Line Items]
Percentage added to Eurodollar base rate before margin (as a percent)	1.00%
Amended 2013 Credit Facility | Eurodollar1 | 2013 Term Loan Facility | Maximum
Line Of Credit Facility [Line Items]
Line of credit, interest rate (as a percent)	0.125%
Sumitomo Credit Facility
Line Of Credit Facility [Line Items]
Loan facility, maximum borrowing capacity | ¥	¥ 3,000,000,000
Line of credit, interest rate (as a percent)	0.50%

DERIVATIVE INSTRUMENTS AND HE52

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Fair Value of Derivative Instruments Reported in Condensed Consolidated Balance Sheets (Detail) - USD ($) $ in Millions	Jul. 01, 2016	Oct. 02, 2015
Derivatives Fair Value [Line Items]
Total derivatives	$ 0.2	$ 0
Foreign exchange forward contracts | Derivatives designated as hedging instruments: | Accrued liabilities
Derivatives Fair Value [Line Items]
Total derivatives	$ 0.2	$ 0

DERIVATIVE INSTRUMENTS AND HE53

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Additional Information (Detail) $ in Millions	9 Months Ended
	Jul. 01, 2016USD ($)
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Net unrealized loss on derivative instruments, before tax	$ 0.3
Derivative, term of contract (in months)	1 month

DERIVATIVE INSTRUMENTS AND HE54

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Outstanding Foreign Currency Forward Contracts (Detail) - Foreign exchange forward contracts - Cash Flow Hedging $ in Millions	Jul. 01, 2016USD ($)
Notional Amount of Derivatives [Abstract]
Notional Value Sold	$ 16.5
Euro
Notional Amount of Derivatives [Abstract]
Notional Value Sold	$ 16.5

DERIVATIVE INSTRUMENTS AND HE55

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Effective Portion of Foreign Currency Forward Contracts Designated as Cash Flow Hedges (Detail) - Derivatives designated as hedging instruments: - Foreign currency forward contracts - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jul. 01, 2016	Jul. 03, 2015	Jul. 01, 2016	Jul. 03, 2015
Derivative [Line Items]
Gain (Loss) Recognized in Other Comprehensive Income (Effective Portion)	$ 0.4	$ 0.3	$ (0.9)	$ 2.3
Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Net Earnings (Effective Portion)	$ (0.7)	$ 0.7	$ (0.6)	$ 3.4

DERIVATIVE INSTRUMENTS AND HE56

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Outstanding Foreign Currency Forward Contracts that Were Entered into to Hedge Balance Sheet Exposures (Detail) - Derivatives Not Designated as Hedging Instrument - Foreign exchange forward contracts $ in Millions	Jul. 01, 2016USD ($)
Notional Value Sold
Derivative [Line Items]
Notional Value	$ 385.5
Notional Value Sold | Australian Dollar
Derivative [Line Items]
Notional Value	18.8
Notional Value Sold | Brazilian Real
Derivative [Line Items]
Notional Value	9
Notional Value Sold | British Pound
Derivative [Line Items]
Notional Value	66.2
Notional Value Sold | Canadian Dollar
Derivative [Line Items]
Notional Value	0
Notional Value Sold | Euro
Derivative [Line Items]
Notional Value	184.9
Notional Value Sold | Hungarian Forint
Derivative [Line Items]
Notional Value	3.5
Notional Value Sold | Indian Rupee
Derivative [Line Items]
Notional Value	12.7
Notional Value Sold | Japanese Yen
Derivative [Line Items]
Notional Value	82.7
Notional Value Sold | New Zealand Dollar
Derivative [Line Items]
Notional Value	1.5
Notional Value Sold | Swedish Krona
Derivative [Line Items]
Notional Value	1.8
Notional Value Sold | Swiss Franc
Derivative [Line Items]
Notional Value	0
Notional Value Sold | Thai Baht
Derivative [Line Items]
Notional Value	4.4
Notional Value Purchased
Derivative [Line Items]
Notional Value	96.4
Notional Value Purchased | Australian Dollar
Derivative [Line Items]
Notional Value	0
Notional Value Purchased | Brazilian Real
Derivative [Line Items]
Notional Value	0
Notional Value Purchased | British Pound
Derivative [Line Items]
Notional Value	0
Notional Value Purchased | Canadian Dollar
Derivative [Line Items]
Notional Value	4.8
Notional Value Purchased | Euro
Derivative [Line Items]
Notional Value	9
Notional Value Purchased | Hungarian Forint
Derivative [Line Items]
Notional Value	0
Notional Value Purchased | Indian Rupee
Derivative [Line Items]
Notional Value	0
Notional Value Purchased | Japanese Yen
Derivative [Line Items]
Notional Value	0
Notional Value Purchased | New Zealand Dollar
Derivative [Line Items]
Notional Value	0
Notional Value Purchased | Swedish Krona
Derivative [Line Items]
Notional Value	0
Notional Value Purchased | Swiss Franc
Derivative [Line Items]
Notional Value	82.6
Notional Value Purchased | Thai Baht
Derivative [Line Items]
Notional Value	$ 0

DERIVATIVE INSTRUMENTS AND HE57

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Gains (Losses) Related to Foreign Currency Forward Exchange Contracts that are Not Designated as Hedging Instruments (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jul. 01, 2016	Jul. 03, 2015	Jul. 01, 2016	Jul. 03, 2015
Derivatives Not Designated as Hedging Instrument | Foreign exchange forward contracts | Selling, general and administrative expenses
Derivative [Line Items]
Amount of Gain (Loss) Recognized in Net Earnings on Derivative Instruments	$ 1.5	$ (1.3)	$ (3.4)	$ 32.7

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Accrued Product Warranty (Detail) - USD ($) $ in Millions	9 Months Ended
	Jul. 01, 2016	Jul. 03, 2015
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]
Accrued product warranty, at beginning of period	$ 45.9	$ 49.3
Charged to cost of revenues	39.6	33.1
Actual product warranty expenditures	(35.5)	(38.8)
Accrued product warranty, at end of period	$ 50	$ 43.6

COMMITMENTS AND CONTINGENCIES59

COMMITMENTS AND CONTINGENCIES - Additional Information (Detail) $ in Millions	1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 30, 2015tender	Jul. 01, 2016USD ($)	Jul. 03, 2015USD ($)	Jul. 01, 2016USD ($)	Jul. 03, 2015USD ($)	Oct. 02, 2015USD ($)
Commitments And Contingencies [Line Items]
Percentage of partner responsibility				33.33%
Environmental cleanup costs, third-party claim costs, project management costs and legal costs		$ 0.3	$ 0.2	$ 0.7	$ 1
Receivables of past and future environmental-related expenditures		2.1		2.1		$ 2.1
Restructuring charges					$ 13.4
Oncology Systems And Imaging Components
Commitments And Contingencies [Line Items]
Restructuring charges		0.8		5.6
Payments for Restructuring				3.5
Cercla sites and one past facility
Commitments And Contingencies [Line Items]
Estimated environmental remediation costs, minimum		1.3		1.3
Estimated environmental remediation costs, maximum		9.9		9.9
Amount accrued for environmental remediation expense		1.3		$ 1.3
Cercla sites and one past facility | Minimum
Commitments And Contingencies [Line Items]
Estimated time frames to resolve contingency related to environmental remediation contingencies, years				1 year
Cercla sites and one past facility | Maximum
Commitments And Contingencies [Line Items]
Estimated time frames to resolve contingency related to environmental remediation contingencies, years				30 years
Other sites
Commitments And Contingencies [Line Items]
Estimated environmental remediation costs, minimum		5.6		$ 5.6
Estimated environmental remediation costs, maximum		25.8		25.8
Amount accrued for environmental remediation expense		$ 7.1		7.1
Estimated environmental remediation costs, best estimate, undiscounted				$ 8.4
Discount rate for environmental remediation costs, net of inflation (as a percent)		4.00%		4.00%
Other sites | Minimum
Commitments And Contingencies [Line Items]
Estimated time frames to resolve contingency related to environmental remediation contingencies, years				1 year
Other sites | Maximum
Commitments And Contingencies [Line Items]
Estimated time frames to resolve contingency related to environmental remediation contingencies, years				30 years
Portugal Investigation
Commitments And Contingencies [Line Items]
Number of tenders | tender	3

RETIREMENT PLANS - Schedule of

RETIREMENT PLANS - Schedule of Net Periodic Benefit Costs (Detail) - Defined Benefit Plans - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jul. 01, 2016	Jul. 03, 2015	Jul. 01, 2016	Jul. 03, 2015
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 1.5	$ 1.2	$ 4.5	$ 3.6
Interest cost	1	1.3	3	3.9
Expected return on plan assets	(1.7)	(1.8)	(5.1)	(5.4)
Amortization of prior service cost	0	0	0	0.1
Recognized actuarial loss	0.7	0.6	2.2	1.8
Net periodic benefit cost	$ 1.5	$ 1.3	$ 4.6	$ 4

RETIREMENT PLANS - Additional I

RETIREMENT PLANS - Additional Information (Detail) - Foreign Pension Plan	Jul. 01, 2016plan
Retirement Plans [Line Items]
Defined Benefit Plan, Number of Plans	7
Defined Benefit Plan, Number Of Immaterial Plans	2
GERMANY
Retirement Plans [Line Items]
Defined Benefit Plan, Number Of Immaterial Plans	1
PHILIPPINES
Retirement Plans [Line Items]
Defined Benefit Plan, Number Of Immaterial Plans	1

INCOME TAXES - Additional Infor

INCOME TAXES - Additional Information (Detail)	3 Months Ended		9 Months Ended
	Jul. 01, 2016	Jul. 03, 2015	Jul. 01, 2016	Jul. 03, 2015
Income Tax Disclosure [Abstract]
Effective tax rate (as a percent)	25.10%	22.10%	26.10%	26.10%

STOCKHOLDERS' EQUITY AND NONC63

STOCKHOLDERS' EQUITY AND NONCONTROLLING INTERESTS - Additional Information (Detail) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Aug. 08, 2016USD ($)shares	Jul. 01, 2016USD ($)	Jul. 03, 2015USD ($)	Jul. 01, 2016€ / shares	Jul. 01, 2016USD ($)	Jul. 03, 2015USD ($)	Jul. 01, 2016USD ($)shares	Nov. 30, 2015shares	Oct. 02, 2015shares	[1]	Apr. 30, 2015
Stockholders’ equity and noncontrolling interests [Line Items]
Number of shares authorized to be repurchased by VMS Board of Directors (in shares)								8,000,000
Number of shares remain available for repurchase (in shares)							4,800,000
Total cost | $		$ 125,513	$ 92,389		$ 374,217	$ 293,570
Common stock, shares outstanding (in shares)							94,306,000		98,070,000
Noncontrolling Interests
Stockholders’ equity and noncontrolling interests [Line Items]
Redemption value | $							$ 10,300
MeVis Medical Solutions AG (MeVis)
Stockholders’ equity and noncontrolling interests [Line Items]
Percentage of voting interest acquired											73.50%
Annual recurring compensation (in euro per share) | € / shares				€ 0.95
Put right (in euro per share) | € / shares				€ 19.77
MeVis Medical Solutions AG (MeVis) | Noncontrolling Interests
Stockholders’ equity and noncontrolling interests [Line Items]
Common stock, shares outstanding (in shares)							480,000
Noncontrolling interest (as a percent)							26.40%
Accelerated Share Repurchase Program
Stockholders’ equity and noncontrolling interests [Line Items]
Total cost | $		$ 0	$ 70,000		$ 40,400	$ 115,000
Subsequent Event | Accelerated Share Repurchase Program With JP Morgan
Stockholders’ equity and noncontrolling interests [Line Items]
Total cost | $	$ 45,400
Repurchased (shares)	500,000
[1]	The condensed consolidated balance sheet as of October 2, 2015 was derived from audited financial statements as of that date, but does not include all disclosures required by accounting principles generally accepted in the United States of America.

STOCKHOLDERS' EQUITY AND NONC64

STOCKHOLDERS' EQUITY AND NONCONTROLLING INTERESTS - Shares Repurchased During Period (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Jul. 01, 2016	Jul. 03, 2015	Jul. 01, 2016	Jul. 03, 2015
Accelerated Share Repurchases [Line Items]
Number of shares (in shares)	1,500	1,000	4,650	3,325
Average repurchase price per share (in dollars per share)	$ 83.68	$ 92.39	$ 80.48	$ 88.30
Total cost	$ 125,513	$ 92,389	$ 374,217	$ 293,570
Accelerated Share Repurchase Program
Accelerated Share Repurchases [Line Items]
Number of shares (in shares)	0	744	519	1,239
Average repurchase price per share (in dollars per share)	$ 0	$ 94.10	$ 77.81	$ 92.84
Total cost	$ 0	$ 70,000	$ 40,400	$ 115,000

STOCKHOLDERS' EQUITY AND NONC65

STOCKHOLDERS' EQUITY AND NONCONTROLLING INTERESTS - Schedule of Accumulated Other Comprehensive Earnings (Loss) and Related Tax Effects (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Jul. 01, 2016	Jul. 03, 2015	Jul. 01, 2016	Jul. 03, 2015
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Balance at beginning of period	[1]			$ 1,726,344
Balance at end of period		$ 1,691,856		1,691,856
Net Unrealized Gains (Losses) Defined Benefit Pension and Post-Retirement Benefit Plans
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Balance at beginning of period				(46,070)	$ (44,060)
Other comprehensive earnings (loss) before reclassifications				0	0
Amounts reclassified out of other comprehensive earnings		(617)	$ (541)	(1,849)	(1,623)
Tax benefit (expense)				(260)	(226)
Balance at end of period		(44,481)	(42,663)	(44,481)	(42,663)
Net Unrealized Gains (Losses) Cash Flow Hedging Instruments
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Balance at beginning of period				0	965
Other comprehensive earnings (loss) before reclassifications				(917)	2,318
Amounts reclassified out of other comprehensive earnings				(589)	3,441
Tax benefit (expense)				122	420
Balance at end of period		(206)	262	(206)	262
Net Unrealized Gains (Losses) Available-for -Sale Securities
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Balance at beginning of period				(112)	0
Other comprehensive earnings (loss) before reclassifications				(440)	(320)
Amounts reclassified out of other comprehensive earnings				(604)
Tax benefit (expense)				(52)	102
Balance at end of period		0	(218)	0	(218)
Cumulative Translation Adjustment
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Balance at beginning of period				(40,281)	(15,516)
Other comprehensive earnings (loss) before reclassifications				906	(28,348)
Amounts reclassified out of other comprehensive earnings				0	0
Tax benefit (expense)				0	0
Balance at end of period		(39,375)	(43,864)	(39,375)	(43,864)
Accumulated Other Comprehensive Earnings (Loss)
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Balance at beginning of period				(86,463)	(58,611)
Other comprehensive earnings (loss) before reclassifications				(451)	(26,350)
Amounts reclassified out of other comprehensive earnings				(3,042)	1,818
Tax benefit (expense)				(190)	296
Balance at end of period		$ (84,062)	$ (86,483)	$ (84,062)	$ (86,483)
[1]	The condensed consolidated balance sheet as of October 2, 2015 was derived from audited financial statements as of that date, but does not include all disclosures required by accounting principles generally accepted in the United States of America.

STOCKHOLDERS' EQUITY AND NONC66

STOCKHOLDERS' EQUITY AND NONCONTROLLING INTERESTS - Schedule of Amounts Reclassified Out of Other Comprehensive Earnings (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jul. 01, 2016	Jul. 03, 2015	Jul. 01, 2016	Jul. 03, 2015
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income On Derivatives [Line Items]
Revenues	$ 789,419	$ 784,011	$ 2,305,319	$ 2,281,271
Net earnings	98,795	113,506	284,793	312,789
Unrealized loss on defined benefit pension and post-retirement benefit plans
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income On Derivatives [Line Items]
Reclassification	(617)	(541)	(1,849)	(1,623)
Unrealized gain (loss) on cash flow hedging instruments
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income On Derivatives [Line Items]
Reclassification			(589)	3,441
Unrealized loss on available-for-sale-investments
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income On Derivatives [Line Items]
Reclassification			(604)
Total amounts reclassified out of other comprehensive earnings
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income On Derivatives [Line Items]
Reclassification			(3,042)	1,818
Net earnings	(1,285)	152	(3,042)	1,818
Reclassification out of Accumulated Other Comprehensive Income | Unrealized gain (loss) on cash flow hedging instruments
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income On Derivatives [Line Items]
Revenues	(668)	693	(589)	3,441
Reclassification out of Accumulated Other Comprehensive Income | Unrealized loss on available-for-sale-investments
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income On Derivatives [Line Items]
Reclassification	$ 0	$ 0	$ (604)	$ 0

STOCKHOLDERS' EQUITY AND NONC67

STOCKHOLDERS' EQUITY AND NONCONTROLLING INTERESTS - Noncontrolling interests (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Jul. 01, 2016	Jul. 03, 2015	Jul. 01, 2016	Jul. 03, 2015
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period	[1]			$ 1,726,344
Net earnings (loss) attributable to noncontrolling interests		$ (91)	$ (136)	(118)	$ (136)
Acquisition of Mevis				0	10,218
Capital contribution from noncontrolling interest holders				0	3,993
Balance at end of period		1,691,856		1,691,856
Increase (Decrease) in Temporary Equity [Roll Forward]
Balance at beginning of period				0	0
Net earnings (loss) attributable to noncontrolling interests				334	0
Acquisition of Mevis				0
Capital contribution from noncontrolling interest holders				0	0
Reclassification of noncontrolling interests in MeVis to redeemable noncontrolling interests				10,382	0
Other				(385)	0
Balance at end of period		10,331	0	10,331	0
Noncontrolling Interests
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period				14,744	0
Net earnings (loss) attributable to noncontrolling interests				(216)	(136)
Reclassification of noncontrolling interests in MeVis to redeemable noncontrolling interests				(10,382)	0
Other				(499)	21
Balance at end of period		$ 3,647	$ 14,368	$ 3,647	$ 14,368
[1]	The condensed consolidated balance sheet as of October 2, 2015 was derived from audited financial statements as of that date, but does not include all disclosures required by accounting principles generally accepted in the United States of America.

EARNINGS PER SHARE - Computatio

EARNINGS PER SHARE - Computation of Net Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Jul. 01, 2016	Jul. 03, 2015	Jul. 01, 2016	Jul. 03, 2015
Earnings Per Share [Abstract]
Net earnings attributable to Varian	$ 98,795	$ 113,506	$ 284,793	$ 312,789
Weighted average shares outstanding - basic (in shares)	94,940	99,721	95,955	100,090
Dilutive effect of potential common shares (in shares)	492	733	567	930
Weighted average shares outstanding - diluted (in shares)	95,432	100,454	96,522	101,020
Net earnings per share - basic (in dollars per share)	$ 1.04	$ 1.14	$ 2.97	$ 3.13
Net earnings per share - diluted (in dollars per share)	$ 1.04	$ 1.13	$ 2.95	$ 3.10
Anti-dilutive employee shared based awards, excluded (in shares)	2,014	948	2,016	994

EMPLOYEE STOCK PLANS - Net Shar

EMPLOYEE STOCK PLANS - Net Share-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jul. 01, 2016	Jul. 03, 2015	Jul. 01, 2016	Jul. 03, 2015
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 12,216	$ 11,356	$ 36,021	$ 36,594
Income tax benefit for share-based compensation	(3,701)	(3,455)	(10,958)	(11,371)
Cost of revenues - Product
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	1,033	1,263	3,141	3,578
Cost of revenues - Service
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	1,114	1,066	3,063	3,004
Research and development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	1,723	1,717	5,046	5,109
Selling, general and administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 8,346	$ 7,310	$ 24,771	$ 24,903

EMPLOYEE STOCK PLANS - Addition

EMPLOYEE STOCK PLANS - Additional Information (Detail) $ in Millions	9 Months Ended	12 Months Ended
	Jul. 01, 2016USD ($)performance_periodshares	Oct. 02, 2015	Sep. 26, 2014performance_period
Stock options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense related to outstanding stock awards | $	$ 13.5
Weighted average period unrecognized compensation expense is expected to be recognized, years	1 year 8 months 9 days
Restricted stocks, restricted stock units, deferred stock units and performance units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense related to outstanding stock awards | $	$ 45.3
Weighted average period unrecognized compensation expense is expected to be recognized, years	1 year 10 months 10 days
Third Amended and Restated 2005 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares counted against the available for grant (in shares)	2.6
Third Amended and Restated 2005 Plan | Performance units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award service period (in years)	3 years
Performance period term			3 years
Third Amended and Restated 2005 Plan | Performance units, company performance
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of performance periods | performance_period	3		1
Performance period term	1 year	1 year
Third Amended and Restated 2005 Plan | Performance units, total shareholder return performance
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Performance period term	3 years	3 years
Beginning Fiscal Year 2016 | Third Amended 2005 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Ratio of maximum payout (in shares)	1.75
Beginning In Fiscal 2015 | Third Amended 2005 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Ratio of maximum payout (in shares)	2
Before Fiscal Year 2015 | Third Amended 2005 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Ratio of maximum payout (in shares)	1.5

EMPLOYEE STOCK PLANS - Fair Val

EMPLOYEE STOCK PLANS - Fair Value with Weighted Average Assumptions (Detail) - $ / shares	3 Months Ended		9 Months Ended
	Jul. 01, 2016	Jul. 03, 2015	Jul. 01, 2016	Jul. 03, 2015
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 months	6 months	6 months	6 months
Risk-free interest rate	0.40%	0.10%	0.30%	0.10%
Expected volatility	18.30%	17.20%	17.60%	12.70%
Expected dividend	0.00%	0.00%	0.00%	0.00%
Weighted average fair value at grant date (dollars per share)	$ 16.60	$ 17.56	$ 16.09	$ 15.87
Employee Stock Option Plans
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	4 years 1 month 17 days	4 years 1 month 17 days	4 years 1 month 17 days	4 years 1 month 24 days
Risk-free interest rate	1.20%	1.30%	1.10%	1.30%
Expected volatility	20.50%	21.60%	20.10%	22.10%
Expected dividend	0.00%	0.00%	0.00%	0.00%
Weighted average fair value at grant date (dollars per share)	$ 15.29	$ 17.16	$ 13.71	$ 18.52

EMPLOYEE STOCK PLANS - Summary

EMPLOYEE STOCK PLANS - Summary of Share-Based Awards Available for Grant (Detail) shares in Thousands	9 Months Ended
	Jul. 01, 2016shares
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant [Roll Forward]
Balance at beginning of period (in shares)	6,661
Granted (in shares)	(2,327)
Cancelled or expired (in shares)	277
Balance at end of period (in shares)	4,611

EMPLOYEE STOCK PLANS - Activity

EMPLOYEE STOCK PLANS - Activity Under Employee Stock Plans (Detail) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended
	Jul. 01, 2016USD ($)$ / sharesshares
Number of Shares
Balance at beginning of period (in shares) | shares	2,537
Granted (in shares) | shares	828
Cancelled or expired (in shares) | shares	(23)
Exercised (in shares) | shares	(377)
Balance at end of period (in shares) | shares	2,965
Exercisable (in shares) | shares	1,664
Weighted Average Exercise Price
Balance at beginning of period (in dollars per share)	$ 72.58
Granted (in dollars per share)	75.97
Cancelled or expired (in dollars per share)	85.95
Exercised (in dollars per share)	52.02
Balance at end of period (in dollars per share)	76.03
Exercisable (in dollars per share)	$ 72.13
Weighted Average Remaining Term (in years)
Balance at end of period (in years)	4 years 7 months 6 days
Exercisable (in years)	3 years 4 months 21 days
Aggregate Intrinsic Value
Balance at end of period | $	$ 26,060
Exercisable | $	$ 20,556
Share price (in dollars per share)	$ 82.60

EMPLOYEE STOCK PLANS - Activi74

EMPLOYEE STOCK PLANS - Activity for Restricted Stock, Restricted Stock Units, Deferred Stock Units and Performance Units (Detail) shares in Thousands	9 Months Ended
	Jul. 01, 2016$ / sharesshares
Number of Shares
Balance at beginning of period (in shares) | shares	950
Granted (in shares) | shares	485
Vested (in shares) | shares	(389)
Cancelled or expired (in shares) | shares	(75)
Balance at end of period (in shares) | shares	971
Weighted Average Grant-Date Fair Value
Balance at beginning of period (in dollars per share) | $ / shares	$ 84.11
Granted (in dollars per share) | $ / shares	77.89
Vested (in dollars per share) | $ / shares	80.98
Cancelled or expired (in dollars per share) | $ / shares	81.86
Balance at end of period (in dollars per share) | $ / shares	$ 82.36

VPT LOANS - Loans and Commitmen

VPT LOANS - Loans and Commitments (Details) - USD ($) $ in Millions	Jul. 01, 2016	Oct. 02, 2015
Long-term notes receivable and Available-for-sale Securities [Line Items]
Available-for-sale securities:	$ 92.4	$ 93
CPTC loans
Long-term notes receivable and Available-for-sale Securities [Line Items]
Commitment	1.9	0
Available-for-sale securities:	92.4	83.9
Loans Receivable
Long-term notes receivable and Available-for-sale Securities [Line Items]
Commitment	22.8	95.6
Long-term	47.8	30.9
NYPC loan | Loans Receivable
Long-term notes receivable and Available-for-sale Securities [Line Items]
Commitment	0	72.8
Long-term	18.5	18.7
MPTC loans (2) | Loans Receivable
Long-term notes receivable and Available-for-sale Securities [Line Items]
Commitment	22.8	22.8
Long-term	$ 29.3	$ 12.2

VPT LOANS - Additional Informat

VPT LOANS - Additional Information (Detail)	Jul. 31, 2015USD ($)	Jun. 30, 2016USD ($)	Jul. 01, 2016USD ($)installment	Oct. 02, 2015USD ($)	May 31, 2015USD ($)installment
Long term notes receivable and available for sale securities [Line Items]
Available-for-sale securities:			$ 92,400,000	$ 93,000,000
NYPC loan
Long term notes receivable and available for sale securities [Line Items]
Accounts receivable from CPTC, includes unbilled accounts receivable			15,300,000
MPTC loans (2)
Long term notes receivable and available for sale securities [Line Items]
Accounts receivable from CPTC, includes unbilled accounts receivable			6,300,000	28,600,000
CPTC loans
Long term notes receivable and available for sale securities [Line Items]
Accounts receivable from CPTC, includes unbilled accounts receivable			30,900,000	25,200,000
CPTC loan facility, Varian's maximum loan commitment			$ 9,700,000
CPTC loan facility, minimum interest rate (as a percent)			9.00%
CPTC loan facility, amortization period over which monthly payments are calculated after January 1, 2015 (in years)			15 years
CPTC loans | Tranche A loan
Long term notes receivable and available for sale securities [Line Items]
Available-for-sale securities:			$ 78,700,000	73,500,000
CPTC loans | Tranche B loan
Long term notes receivable and available for sale securities [Line Items]
Available-for-sale securities:			11,100,000	10,400,000
CPTC loans | Tranche C Loans
Long term notes receivable and available for sale securities [Line Items]
Available-for-sale securities:			$ 2,600,000
CPTC loans | London Interbank Offered Rate (LIBOR)
Long term notes receivable and available for sale securities [Line Items]
CPTC loan facility, interest rate margin (as a percent)			7.00%
Varian Medical Systems, Inc. | CPTC loans
Long term notes receivable and available for sale securities [Line Items]
CPTC loan facility, Varian's maximum loan commitment			$ 4,400,000
Loans Receivable
Long term notes receivable and available for sale securities [Line Items]
Long-term			47,800,000	30,900,000
Loans Receivable | NYPC loan
Long term notes receivable and available for sale securities [Line Items]
Maximum lending commitment	$ 91,500,000
Long-term			$ 18,500,000	18,700,000
Loans Receivable | MPTC loans (2)
Long term notes receivable and available for sale securities [Line Items]
Maximum lending commitment					$ 35,000,000
Interest rate (as a percent)			12.00%
Long-term			$ 29,300,000	$ 12,200,000
Number of annual payments | installment					3
Number of installments | installment			2
Installment payment amount			$ 11,400,000
Loans Receivable | Reclassification From Long-Term Notes Receivable | MPTC loans (2)
Long term notes receivable and available for sale securities [Line Items]
Interest rate (as a percent)			15.00%
Long-term			$ 17,000,000
Senior First Lien Loan | NYPC loan
Long term notes receivable and available for sale securities [Line Items]
Maximum lending commitment	$ 73,000,000
Financing Receivable, Aggregate Principal Amount Funded		$ 10,500,000
Term (in years)	6 years
Interest rate (as a percent)	9.00%
Senior First Lien Loan | Deutsche Bank
Long term notes receivable and available for sale securities [Line Items]
Proceeds from assignment		$ 8,300,000
Discount		3.00%
Senior Subordinated Loans | NYPC loan
Long term notes receivable and available for sale securities [Line Items]
Maximum lending commitment	$ 18,500,000
Term (in years)	6 years 6 months
Interest rate (as a percent)	13.50%
Roll Over Loan | MPTC loans (2)
Long term notes receivable and available for sale securities [Line Items]
Notes receivable					$ 10,000,000
Accrued interest					$ 2,200,000
Selling, General and Administrative Expenses | Senior First Lien Loan | Deutsche Bank
Long term notes receivable and available for sale securities [Line Items]
Gain/loss on sale		$ (2,200,000)

SEGMENT INFORMATION - Additiona

SEGMENT INFORMATION - Additional Information (Detail)	9 Months Ended
	Jul. 01, 2016segment
Segment Reporting [Abstract]
Number of Reportable Segments	2

SEGMENT INFORMATION - Operating

SEGMENT INFORMATION - Operating Results Information for Each Reportable Segment (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jul. 01, 2016	Jul. 03, 2015	Jul. 01, 2016	Jul. 03, 2015
Segment Reporting Information [Line Items]
Revenues	$ 789,419	$ 784,011	$ 2,305,319	$ 2,281,271
Operating Earnings (Loss)	130,469	144,244	381,102	419,730
Corporate
Segment Reporting Information [Line Items]
Operating Earnings (Loss)	(26,600)	600	(46,600)	(30,800)
Operating Segments | Oncology Systems
Segment Reporting Information [Line Items]
Revenues	605,200	558,700	1,778,600	1,711,400
Operating Earnings (Loss)	142,500	110,600	387,200	362,600
Operating Segments | Imaging Components
Segment Reporting Information [Line Items]
Revenues	146,700	134,700	431,800	456,200
Operating Earnings (Loss)	28,200	23,200	79,100	104,400
Operating Segments | Total reportable segments
Segment Reporting Information [Line Items]
Revenues	751,900	693,400	2,210,400	2,167,600
Operating Earnings (Loss)	170,700	133,800	466,300	467,000
Operating Segments | Other
Segment Reporting Information [Line Items]
Revenues	37,500	90,600	94,900	113,700
Operating Earnings (Loss)	$ (13,600)	$ 9,800	$ (38,600)	$ (16,500)